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Abstract
In order to perform reliably and protect against unpredictable attackers, immune
systems are organized via complex, hierarchical cooperativity. This organization
is necessary for their function and a tremendous challenge to their understand-
ing that has motivated contributions from many outside fields. Our approach to
studying the immune system computationally has been pragmatic: we have ap-
plied any analysis method necessary to understand questions motivated by exper-
imental biology, rather than use biology specifically to discover new physics or
methods. Our approach has led us to study problems that span a wide range of
time and length scales and require a diverse set of solutions. This thesis describes
three projects that span the extremes of this range, from nanometers over nanosec-
onds to organism-wide responses over hours.
The first project was motivated by a puzzle: experimentalists had reached op-
posing conclusions on the role of a peptide fragment in the main protein interac-
tion responsible for immune recognition. We used molecular dynamics simula-
tions of the proteins to resolve the contradiction by creating a unifying model.
The second and third projects jump from the molecular to the system-wide. In
the second project, we sought to understand which phenotypes of cancer-fighting
immune cells were the most important. To do this, we developed novel data vi-
sualizations and applied multivariate dimensionality reduction and regression to
understand high-dimensional immunotyping data collected on the phenotypes.
The final project addressed an important question in immunology: how accu-
rately do blood assay results reflect the immune response in the tissues, where it
matters most? We explored this relationship using a supervised learning model of
a highly multidimensional dataset that combined blood and tissue measurements.
We found that the two environments could be drastically different and that the
relationship mapping blood to tissue was complex.
Combined, these three projects highlight the variety of scientific questions and
richness of insight that occur at the intersection of immunology and computation.
Thesis Supervisor: Arup K. Chakraborty, Ph.D.
Title: Robert T. Haslam Professor of Chemical Engineering
Professor of Chemistry and Biological Engineering
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Chapter
Introduction
This thesis summarizes several years of work toward understanding the immune
system with computational tools and simulations. The immune system is one of
the most complex areas of biology imaginable. Because it deals directly with fight-
ing disease, and its aberrant behavior is responsible for so many other diseases, it is
also at the forefront of a great amount of medical research. Advances in immunol-
ogy have tremendous potential to relieve the untold amount of suffering caused
by viruses such as hiv and autoimmune disorders, such as diabetes. With the
emergence of computational biology and biophysics, engineers, chemists, physi-
cists and computer scientists have all been enticed by immunology. Our work falls
into this greater context. Apart from the potential human benefits and the inher-
ently interesting biology, immunology offers quantitative researchers a tremen-
dous field of potential and complexity to parse. The system works through hierar-
chically structured cooperativity, which means that significant processes happen
in a variety of temporal and spatial scales. All of these processes must be made
clearer, with new techniques and new analyses, and it is this rich world of emer-
gent behavior and nontrivial interaction that draws quantitative scientists in.

. The immune system
The immune system is essential to higher organisms’ survival. It protects its host
from invading viruses and other pathogens through a wide ensemble of defense
methods. The methods can be divided into two major parts: the innate immune
system, which is built to recognize common patterns of pathogens and destroy
them, and the adaptive immune system, which trains a diverse repertoire of cells
(T lymphocytes) to recognize pathogens that may never have been seen before, and
remember any new pathogens encountered.
Our work is concerned mostly with the adaptive immune response. In this
response, the pathogen is absorbed by the host’s own cells, either via infection or
phagocytosis by innate immune cells. The pathogen’s proteins are cut up into short
peptide fragments and displayed as antigen on the surface of the consuming cell,
held in bun-like structures of surface receptors called mhcs. When T lymphocytes
encounter the surface of the antigen-presenting cells, their specialized receptor
(tcr), binds to the peptide-mhc complex [,]. If the reaction is sufficiently strong,
the T cell detects the presence of infection and begins to orchestrate a series of
effector functions [].
After detection occurs, the immune system organizes a complex, multi-pronged
response, incorporating many cell types and many strategies for pathogen con-
trol. The amounts of coordination necessary to implement such a response are
achieved through the help of cytokines: small inter-cellular proteins released as
signals. Common examples are il-2, a cytokine which signals T cell proliferation,
and tgf-β, a cytokine that usually inhibits an inflammatory response. Cytokines
exist in a wide variety of forms and send a wide variety of messages: the same
cytokine in different combinations can have different effects []. Through their
variety and complexity, cytokines provide a rich window into the functions of the
innate and adaptive immune system. Their study is of particular interest to a sys-

tematic understanding of immune responses at larger scales.
. Scope of the work and choice of methods
Computational immunology is a tremendously varied field, emerging from the
need to systematically understand the tiered complexity of the immune system
and to interpret the ever more complicated laboratory results emerging today. Re-
cent efforts in the field have combined advanced experimental techniques with
analysis techniques originally from financial analysis, stochastic processes, chemo-
metrics, machine learning, chemical kinetics, and neurobiology [–].
The scope of our work does not lie in developing new contributions in any of
the original fields from which these techniques came, it does not lie in developing
new techniques for their own sake, and it does not lie in immunology experiments.
Rather, our contributions come from bringing computational techniques to bear
on relevant immunological questions, often in novel ways. The question we ask is,
“how can we use currently existing techniques to answer the biologically relevant
question?” Such synthesis of computational techniques with immunological data,
ever with an eye toward biological relevance, can produce novel insight and bring
new interpretability to the imaging and multiplexing techniques that have recently
revolutionized the field.
The optimal method to use in solving a problem depends on the questions be-
ing asked. For questions at the molecular level that involve individual proteins
interacting with one another, molecular dynamics is a highly appealing solution
for its ability to provide a direct answer. For questions that deal with the immune
system as a whole, a variety of methods exist. Within the large scope of systematic
immune questions, one frequently recurring problem is to find a way to model,
explore, and understand highly multidimensional data, which does not lend it-

self readily to traditional analysis methods or charts. Multivariate statistics and
machine learning offer a powerful tool set for these tasks.
Our work seeks to answer two classes of problems. The problems differ greatly
from one another and serve as bookends for the kinds of temporal and spatial
scales addressed in contemporary computational immunology. The first type of
problem involves the impact of a peptide on protein binding. Its spatial scale is
nanometers and its timescale is nanoseconds, making molecular dynamics sim-
ulations an appropriate technique to use. The second class of problem requires
the analysis of multidimensional data collected at multiple timepoints throughout
a human or mouse immune system. Its spatial scale spans the entire organism,
and its time scale can extend to days. Since the goal is to understand and inter-
pret data that has already been collected, multivariate statistical techniques are
the right class of methods to deal with this class of problem.
The remainder of this chapter explores the techniques outlined above in greater
detail. Chapter , which is adapted from a paper published in the Journal of Phys-
ical Chemistry B [], describes our use of molecular dynamics to understand the
subtle influence of the peptide on the interface between tcr and allo-mhc, cover-
ing the first class of problem. Chapters  and  conclude the thesis and describe
the other end of the spectrum of our work, the second class of problem. They
are pre-print manuscripts of two detailed case studies of the successful applica-
tion of dimensionality reduction and latent variable regression analyses to highly
multidimensional immunological datasets.
. Molecular dynamics simulation
When the answer to an immunological question rests on the interactions between
proteins, molecular dynamics provides a way to answer it. The technique was orig-

inally developed in pure physical simulation []. Since its inception, however, it
has been used heavily in more applied fields, such as material science [] and
biology [–]. Molecular dynamics attempts to describe the structural and dy-
namical properties of a system by solving its classical equations of motion numeri-
cally, given a starting state. In biology, the system in question is a large biomolecule
and potentially its surrounding environment. Every atom in the system is de-
scribed classically. The initial position is usually obtained from a crystal structure,
or a homology or docking model based on another crystal structure. With molecu-
lar dynamics, we can answer the question, “How do these proteins move?” We can
also sometimes answer the question, “If we change this part of a system, what will
happen?” This lets us address many questions at the heart of immunology for any
protein with a sufficiently accurate crystal structure, such as many types of mhcs
and tcrs [,], signaling molecules such as Ras [], or cytokines [].
The chaotic nature of the classical equations of motion, combined with the
large number of atoms to resolve mean that with current computing power, molec-
ular dynamics can typically address scales on the order of hundreds of monomers,
for on the order of tens of nanoseconds []. Extension of these scales by more
than an order of magnitude is possible with a variety of coarse graining and ap-
proximation techniques, which are beyond the scope of this introduction.
When molecular dynamics simulations are performed on biomolecules, the
molecules are modeled as systems of atoms with mass and charge, connected by
spring-like bonds and subject to a host of other long and short-range interactions,
such as dihedral angles, electrostatic interactions, and Van Der Waals interactions.
These interactions are parameterized for each atom type considered and tabulated
in a comprehensive data structure called the force field. Different force fields
contain different parameter values, use different types of terms, assume differ-
ent molecule topologies. As a concrete example, we will use the charmm poten-

tial [], a widely used force field. In the most direct form of dynamics with the
charmm potential, each atom i with position ri is subject to the classical equation
of motion
mr¨i = Fi = −∇iV (r1, . . . ,rN ), (.)
where V is determined by the charmm potential:
V (r1, . . . ,rN ) = V (R) = Vb(R) +Vθ(R) +Vϕ(R) +Vω(R)︸                                  ︷︷                                  ︸
bond terms
+Vel(R) +VVdW(R)︸               ︷︷               ︸
non-bond terms
+Vrestr(R)︸   ︷︷   ︸
restraints
(.)
The individual terms represent the different types of bonding and non-bonding
interactions the atoms in the system are subject to, plus any external restraints.
We address the terms individually, treating the tabulated parameters of the force
field as functions of atom index of the form f (i, j,k, l).
The bonding term Vb is a simple harmonic spring:
Vb(R) =
∑
(i,j)∈B
kb(i, j)
[
rij − r0(i, j)
]2
, rij = |ri − rj |, (.)
where B is the set of all bonded atom pairs in the structure, and kb and r0 are force
constants and equilibrium bond lengths, parameterized in the force field by the
types of atoms i and j.
The angle term Vθ is also a harmonic spring, but now in the angle space:
Vθ(R) =
∑
(i,j,k)∈Θ
kθ(i, j,k)
[
θ(ri,rj ,rk)−θ0(i, j,k)
]2
, (.)

where Θ is the set of all bond-bond angles in the structure, θ(ri,rj ,rk) is the angle
between the three atoms, and kθ and θ0 are force constants and equilibrium bond
angles, parameterized as above.
The proper dihedral angle term Vϕ represents the gauche steric effects of atoms
rotating around a bond with a periodic term:
Vϕ(R) =
∑
(i,j,k,l)∈Φ
|kϕ(i, j,k, l)| − kϕ(i, j,k, l)cos
[
n(i, j,k, l)ϕ(ri,rj ,rk,rl)
]
, (.)
where Φ is the set of all dihedral angles in the structure, ϕ(ri,rj ,rk,rl) is the di-
hedral angle including the four atoms, kϕ is the force constant, and n ∈ {1, . . . ,6}
specifies how many groups are rotating around the bond.
The improper dihedral angle term Vω is a harmonic restraint in dihedral space
added to maintain chirality and planarity in certain configurations, such as car-
bonyl groups []:
Vω(R) =
∑
(i,j,k,l)∈Ω
kω(i, j,k, l)
[
ω(ri,rj ,rk,rl)−ω0(i, j,k, l)
]2
, (.)
where Ω is the set of all improper dihedrals in the structure, ω(ri,rj ,rk,rl) is the
improper dihedral including the four atoms, and kω and ω0 are force constants
and equilibrium bond angles, parameterized as above.
The non-bond terms are calculated pairwise for the atoms in the system, which
grows as N2. These terms are often the most computationally expensive to calcu-
late and are subject to simplification with cutoffs and scaling of shifting algorithms
that are also beyond the scope of this introduction, but are explained in detail in
the pertinent papers [,]. In the following equations, these algorithms will be
represented by the scale factor δij ≥ 0, which depends on the algorithm. For atoms
that do not interact, δij = 0.

The electrostatic non-bond terms in the charmm potential are calculated with
Coulomb’s law:
Vel(R) =
N∑
i=1
N∑
j=1
δij
q(i)q(j)
4pirij
, (.)
where q represents atoms’ charge, rij , as defined earlier, is the distance between
them, and  is the dielectric constant, which may be changed depending on the
environment, or given functional dependence.
The Van der Waals interactions responsible for the London dispersion forces
between the atoms are approximated by the Lennard-Jones potential []:
VVdW(R) =
N∑
i=1
N∑
j=1
δij
[
A(i, j)
rij12
− B(i, j)
rij6
]
, (.)
where A and B are parameterized values that are simple functions of the dielectric
and the Van der Waals radii of atoms i and j.
Once the initial position is set and the parameters are known, initial velocities
are assigned to the atoms, most often from a Maxwell-Boltzmann distribution, sol-
vent is added, if necessary, and the equations of motion are solved as a trajectory.
The positions of the atoms and any other properties of interest are periodically
recorded for later analysis. After the trajectory has equilibrated, we can run it
further to observe realistic behavior of the protein by viewing movies of the dy-
namics. From the equilibrated section of the trajectory, we can also calculate struc-
tural properties, correlation functions, and thermodynamic quantities to obtain a
complete physical description of the system.
Because of the starkness of the approximations and assumptions, molecular dy-
namics calculations do not always provide accurate results. Sometimes, this is due
to a poor initial condition from an insufficiently defined model of the structure.
Sometimes, this is due to a bad choice of parameters. Despite the many potential
opportunities for error, simulations can be verified by comparing to known results

and thereby serve as reliable indicators of molecular behavior.
For all of the above-mentioned strengths, molecular dynamics simulations have
been used many times to explain the behavior of key immunological proteins
[–] and were the ideal calculations to perform to understand the role of the
peptide in alloreactivity.
. Dimensionality reduction and latent variable re-
gression methods
As explained above, Molecular Dynamics can serve as an incredibly effective win-
dow into the behavior of the key proteins involved in immunology. But neither
it—nor any other type of simulation—is a complete solution. Often, there is not
enough data to permit the construction of a model that can be simulated. More
importantly, the questions asked may not be appropriate for simulation.
Another type of question that frequently emerges in immunology is to find
the overall structure and most important variables in a highly multidimensional
dataset. Answering this question requires techniques such as exploratory data
analysis (unsupervised learning) [] and regression (supervised learning), often
in combination. When successful, these techniques identify which relationships
and degrees of freedom are the most important, which observations are outliers,
and sometimes construct a consistent model of the data that elucidates the under-
lying biology and suggests further experiments.
The recent need for regression and exploratory analysis is spurred by the con-
comitant rise in multiplexing instruments, which can simultaneously measure
many analytes [, ], and systematic experimental approaches, which seek to
understand a biological system by measuring a diverse set of indicators [–].
However, no advance in instrumental technology or approach can alleviate one of

the fundamental difficulties of biological experiments: data from living organisms.
No matter how much information is collected about a particular mouse, an exper-
iment can only use a small number of them. The live organism constraint means
that, in addition to many dimensions, the new datasets have few observations.
Such datasets are a challenge to analyze, because of the difficulty of understanding
multidimensional variation and because of the large potential in variability that
comes from small sample sizes. Fortunately, robust statistical methods have been
developed for regression and exploratory analysis of these datasets. Our work has
aimed to bring clarity to complex immunological phenomena through judicious
application of these simple yet powerful techniques.
The term exploratory analysis is a broad umbrella that encompasses many tech-
niques, including a multitude of clustering approaches. Within that umbrella,
we have decided to focus on latent variable techniques for dimensionality reduc-
tion. These approaches seek to find new (latent) variables, that capture the es-
sential aspects of the data in fewer dimensions. The data, once projected into the
lower-dimensional representation, can then be subjected to regression techniques
to identify key relationships among the variables. The simplicity of the techniques
comes from the straightforward, linear nature of both the latent variable calcula-
tion and the regression. It may seem counterintuitive at first to model potentially
nonlinear data with such a strictly linear model. But the benefits that linearity
brings to interpretation are unparalleled. And given the qualitative nature of ex-
ploratory analysis, a linear analysis is often sufficient: what matters is not the
most accurate model, but an understanding of the essential variables and degrees
of freedom, a qualitative picture of a complex system. For this purpose, the tech-
niques we highlight below are ideal.

.. Principal component analysis
Principal component analysis (pca) is a basic exploratory data analysis technique.
It is one of the simplest ways to project a dataset onto a useful set of reduced
dimensions. Because of its simplicity, is ubiquitous in many fields [], and its key
ideas underlie much of the rest of the techniques used in our work.
The essential idea behind pca is, given data in many dimensions, to create a
new, smaller set of latent variables that span as much of the data as possible. These
latent variables are called principal components (pcs). Looking at the data in the
space of the pcs can reveal interesting grouping and clustering of the data. Iden-
tifying which of the original (manifest) variables contribute to the pcs can reveal
correlated groupings of the manifest variables that display the most impact in the
data. The pcs are defined as linear combinations of the manifest variables. In order
to span as much of the data as possible, the latent variables are determined by an
optimization process subject to two essential constraints:
. every pc must have unit norm, i.e. the squares of the weights must sum to 1.
. all of the pcs must be completely perpendicular to one another
There are many potential criteria to optimize subject to these constraints, but pca
chooses to optimize variance. With the optimization criterion and constraints de-
fined, the pcs are calculated one-by-one. That is, the first principal component of a
dataset is a unit-norm linear combination of the manifest variables with maximum
variance. The second principal component is the unit-norm linear combination of
the manifest variables with maximum variance that is orthogonal to the first pc.
The third pc is the same, orthogonal to both the first and second pc, and so on. In
principle, there are as many pcs as there are original variables. But the amount
of variance remaining for each consecutive pc shrinks drastically, so the data is
usually projected onto only the first few.

The discussion is much clearer in mathematical terms. In our analysis, we will
assume that each manifest variable in the data is already mean-centered. This
simplifies the mathematics without restricting the generality of the technique. For
a completely rigorous mathematical treatment, we recommend the work of Jolliffe
[]. Thus, given an n×m matrix of mean-centered data X, whose columns are the
m manifest variables
(
X =
[
x(1) . . . x(m)
])
, and whose rows correspond to individual
observations or samples, pca seeks to find the matrixW ∈Rm×Ra, a ≤m, such that
T = XW is the data projected into the reduced (a ≤m) dimensional representation.
The n × a matrix T is known as the score matrix, and W is known as the loading
matrix. The orthogonality and normalization constraints are summarized in the
relationship W TW = Ia, where Ia is the a× a identity matrix.
A straightforward derivation [] shows that W can be obtained by calculat-
ing the eigenvectors of the covariance matrix K = 1n−1X
TX, such that W T0 LW0 = X,
whereW0 is the matrix of eigenvectors, and L is a matrix with only the correspond-
ing eigenvalues on the diagonal. Intuitively, this eigenvalue decomposition makes
sense. K represents all of the variance and covariance in the data. Its diagonal
elements are the variances of each individual variable. Because the columns of X
are mean-centered,
var
(
x(i)
)
=
1
n− 1
n∑
`=1
(
x
(i)
`
)2
=
x(i) · x(i)
n− 1 = (K)ii = kii.
Its off-diagonal elements are, by analogy, the covariances
cov
(
x(i),x(j)
)
=
1
n− 1
n∑
`=1
x
(i)
` x
(j)
` =
x(i) · x(j)
n− 1 = (K)ij = kij .
Geometrically, the eigenvectors of K represent the set of axes within K with the
greatest possible extent, indicated by their eigenvalue. Therefore, just as the eigen-
values with the largest eigenvalues represent the most essential spatial dimensions

of a matrix, the principal components represent the dimensions in the data with
the greatest variation in them. Variation is not a perfect proxy for significance, but
it is a simple and effective marker nonetheless.
Because K is a square, symmetric matrix, the pcs, i.e., the columns of W0, are
defined to be orthonormal. Furthermore, the variance of every pc is equal to the
eigenvalue of the corresponding eigenvector, so the first a pcs (W ) can be obtained
by simply sorting the columns ofW0 by eigenvalue and keeping the first a columns.
The eigenvalue definition can be extended further with singular value decom-
position (svd). Because the left-singular vectors of an svd of a matrix M are equiv-
alent to the eigenvectors of the matrix MTM, W can be obtained directly from the
left singular vectors of an svd of X. The missing scale factor of 1n−1 only affects the
eigenvalues and it can be compensated for directly. This approach has the added
benefit of automatically putting the most significant vectors first.
If all of the eigenvectors are kept in W (a = n), then our original definition of
the score matrix T rearranges into a decomposition:
T = XW
TW T = XWW T
X = TW T . (.)
When not all components are kept (a < n), this decomposition is not exact, but
it nevertheless serves as a useful reformulation of pca in terms of a model of the
data. The first a pcs are thus the a first and most most significant components in
the spectral decomposition of X [].
The score matrix T represents the data in the lower-dimensional space of the
principal components. By exploring this lower-dimensional space visually or with
other algorithms, it is possible to detect groups of related observations, or deter-

mine patterns. One common pattern is for a pc to partition the observations into
distinct groups. This separation arises naturally, from the correlations in the data,
rather than any human involvement or parameterization. Another common pat-
tern is the emergence of clusters with a space of several pcs. These patterns are
usually detected visually through the use of scatterplots and biplots [].
The loading matrix W represents the pcs in terms of the original manifest vari-
ables. A column in W shows the loadings that define a pc. The sign convention for
each column is arbitrary, so the absolute sign of a loading is unimportant: only dif-
ferences between signs and magnitude of loadings matter. The first pc represents
the overall amount of covariation in the data and in most cases will have univer-
sally positive or negative loadings for all of the variables. Often, the columns will
highlight certain variables with large loadings. Some will draw contrasts between
related groups of variables by assigning them opposite signs. The loadings thus
reveal information about the manifest variables in two ways. First, the more rel-
evant a variable is in an early pc, the more likely it is to be associated with some
important underlying degree of freedom in the data; second, more than simply
identifying the important varibles, the groups of loadings identify variables that
vary similarly. This dual purpose makes pca a powerful analysis technique despite
its simplicity.
.. Multiple linear regression
While pca is a tremendously powerful technique for finding important correla-
tions among a single block of data, we often want to find relationships between
two blocks of data and perhaps to build a model that can capture that relation-
ship. This general problem is called regression, or supervised learning, and for
our purposes, we will restrict ourselves to linear relationships.
The linear regression problem seeks to find a matrix B such that Yˆ = XB is

optimally close to Y according to some measure, usually a sum ε of squared error
terms:
E =
(
eij
)
= Y − Yˆ
ε =
n∑
i=1
mY∑
j=1
eij
2. (.)
The simplest solution to this problem is to use all the data in X and Y to cal-
culate B directly, since it can be derived that the expression B =
(
XTX
)−1
XTY
minimizes ε. However, this approach is frequently inadequate to deal with noisy
or co-linear data. In the latter case, XTX is singular, so B is necessarily undefined.
In the former case, because all of the data are used in the fit, noisy data are fit as
well, which easily leads to over-fitting. As for its practical uses, linear regression
is too ubiquitous to mention in depth, due to its simplicity and ease of implemen-
tation [].
.. Principal component regression
Multiple strategies are in use for resolving the noise and collinearity issues, and a
common family of strategies is known as latent variable regression. Latent vari-
able regression methods project X and/or Y onto a (usually smaller) set of latent
variables, defined and optimized as above.
The simplest latent variable regression method is called principal component
regression (pcr) [,]. Here, the latent variables are principal components (pcs)
of X, as calculated by pca []. The pcs are calculated from a singular value de-
composition (svd) ofX, and Y is fit to a subset of the a highest-scoring pcs. Because
the pcs are orthogonal to one another, pcr eliminates the problem of co-linear vari-
ables. And if the largest directions of variation inX overlap well with the variation
in Y , pcr can provide robust and accurate models. However, this is rarely the case

in real life: there is nothing that ensures that the principal components of X over-
lap with variation in Y at all. In fact, the first principal components of real X
datasets are frequently devoted to outlier detection, which categorically does not
relate to Y . So, while pcr can be a simple and effective technique in some situa-
tions, it often falls short.
.. Partial least squares projection onto latent structures (pls)
Partial least squares projection onto latent structures (pls) is an effective strategy
for overcoming the limitations of pcr at the cost of increased model complexity.
Instead of, as in pcr, constructing a reduced-dimensional representation ofX from
an svd of X, pls constructs it from an svd of the cross-correlation matrix K = XTY
[]. This approach to finding a pls regression (simpls) is shown in Algorithm .
Unlike pcr, pls produces two sets of scores and loadings, although both are
based on T , the set of X scores. The benefit of this more elaborate output is a flex-
ible and powerful algorithm for modeling diverse datasets. The optimal number
of components a? can be set deterministically through cross-validation. Once this
number is determined and the algorithm is run a final time, the model that results
contains two decompositions and one regression.
x score-loading decomposition, error term: X = T PT +E (.)
y score-loading decomposition, error term: Y = UQT + F (.)
Predicting Y from the x-scores: Y = T QT +G (.)
Predicting Y directly from X: Y = XB +G (.)
The decompositions above work exactly like the pca decomposition described
earlier, even if the loadings are obtained in a slightly different process.

Algorithm  simpls
Require: Data matrices X, Y , and a maximum dimension number a.
Ensure: The matrices P,Q, T , U , W , and B fully specify a pls model of Y vs X.
K← XTY
:
for all i ∈ {1, . . . , a} do
WSCT = K . Compact svd of K
:
wi← the first column of W
ti← Xwi . x-scores for component i
: ti← ti/
(
tiT ti
)
. Normalize ti
pi← XT ti . x-loadings for component i: a least-squares fit of X to ti
qi← Y T ti . y-loadings come from a least-squares fit of x-scores!
: ui← Y Tqi . y-scores for component i
V ← an orthogonal basis of i vectors constructed from {pi}.
: K←K −V
end for
: P← [p1| . . . |pa] . Combine into matrices
Q← [q1| . . . |qa]
T ← [t1| . . . |ta]
: U ← [u1| . . . |ua]
W ← [w1| . . . |wa]
B←W
(
T TT
)−1
QT . The regression matrix

Although pls models incorporate variation from Y , the projection is still more
fundamentally dependant on the X because the y scores and loadings U and Q
come directly from the x scores T . Such a restriction does not preclude a diverse
world of data, however, and pls, which was applied first to chemometric analysis
of spectra [] has successfully been used to model everything from human taste
preferences [] to cell signaling networks [,,].
Despite their ubiquity, flexibility and power, plsmodels can still produce mean-
ingless, uninterpretable results. A key factor necessary for the interpretability of
results is score-loading correspondence [], the similarity of the loadings P—
obtained from a least-squares fitting of the data X onto the scores T—to the orig-
inal weights W responsible for making the scores. For the model to make sense,
W and P should correspond well. In pca, because of the nipals calculation algo-
rithm, P and W are equal by definition []. In pls, however, this is no longer
true, because the information from Y impacts the loadings. Because of the corre-
lation, any parts of X uncorrelated with Y act as structured noise, which is still
captured by the model. Such noise is problematic. While pls models are robust to
a certain degree of noise, too much noise, particularly structural noise, can make
interpretation of the loadings much more difficult []. Sometimes, the noise is
limited to only certain variables (columns) in X or Y , which has led to a host of
complex optimization techniques for removing “noisy” variables from the regres-
sion data [,–]. These algorithms add many parameters and long simulation
times to the process. Due to the exponentially large number of possible variable
combinations, it is usually impossible to be certain of picking a truly optimal vari-
able subset. A simpler, more informative, and more effective approach is instead
to filter out this noise directly, which the extensions of pls o-pls and o-pls do.

.. o-pls and o-pls
The core of o-pls, and its sibling o-pls, which allows for multidimensional y data,
is to use the underlying structure of of pls, but to improve the interpretability of
the model by adding an Orthogonal Signal Correction (osc) filter to remove the
structured noise in both X and Y [, ]. The osc filters deflate the data matri-
ces by anything orthogonal to the correlation between them. Since the structured
noise in the data is by definition uncorrelated with the relationship between the
data, the filters capture and remove much of the structured noise. This splits the
model up into two parts: a predictive part, consisting entirely of the correlations
between X and Y , and an orthogonal part, consisting of the noise in X and the
noise in Y .
In addition to their main purpose, the filters provide the ancillary benefit of a
latent-variable analysis of the noise they filter out: the noise matrix is constructed
from principal components defined by scores and loadings, in analogy to the cor-
related part of the model. The introduction of osc also changes the dependence
of the model. Since X and Y are both filtered using the same technique, they
are now of equal importance, and two equally valid regressions are established
between them. The symmetry between the data blocks allows o-pls to apply
without hesitation to situations—e.g. correlations between serum and tissue cy-
tokine levels—in which either data block could conceivably be considered the in-
dependent variable set. o-pls’s features combine to produce a model with more
elements, but even greater flexibility and interpretability with less cost and com-
plexity than variable selection, and additional insight:

x decomposition: X = T PT +XYo +E (.)
y decomposition: Y = UQT +YXo + F (.)
Orthogonal decomposition of X: XYo = TYoPYo
T (.)
Orthogonal decomposition of Y : YXo = UXoQXo
T (.)
Predictive regression of X onto Y : T = UBU→T +HU→T (.)
Predictive regression of Y onto X: U = T BT→U +HT→U (.)
Note that, in this situation, the predictive regression is symmetric and estab-
lished between the scores, rather than between X and Y directly. Thus, if a model
is already established, in order to predict the model’s estimates for new data, the
orthogonal components must be filtered out before the estimates are calculated.
In analogy with simpls, the o-pls algorithm is based on a singular value de-
composition of the correlation matrix K, but rather than consistent deflation of K,
X and Y are deflated themselves using their projections onto a vector space orthog-
onal to the principal components of K. At the end, the deflations are augmented
to form the orthogonal projections. An outline of the full procedure is described
in Algorithms  and. As input, it takes the data matrices X and Y , along with the
number of predictive, X-orthogonal, and Y-orthogonal components to keep.
o-pls can be combined with other variable selection techniques, but because
of the osc filter, this is rarely necessary. Instead, the final model is chosen by pick-
ing optimal component numbers a, aXo , and aYo by minimizing a cross-validation
error, by a visual scree plot technique [,], or by some combination of the two.
The outcome is a powerful, informative, flexible, and expressive model that cap-
tures and analyzes a wide range of variation in the data to provide useful insights.

Algorithm  o-pls, Part 
Require: Data matrices X, Y , and maximum dimension numbers a, aYo , and aXo .
Ensure: The matrices P,Q, T , U , PYo ,QXo , TYo , UXo , BU→T , and BT→U fully specify
an o-pls model of Y vs X.
K← XTY
: WSCT = K . Compact svd of K
W ←W
(
W TW
)− 12 . NormalizeW ,C
: C← C
(
CTC
)− 12
W ← the first a columns of W
C← the first a columns of C
:
for all i ∈ {1, . . . , aYo} do . osc on X
T ← XW
: P← XTT
(
T TT
)−1
KYo ← P −WW TP . P, orthogonalized to W : heart of osc
:
Subtract out most significant component of KYo from X:
WYoSYoC
T
Yo
= KYo . Compact svd of KYo
:
w
(i)
Yo
← the first column of WYo
t
(i)
Yo
← Xw(i)Yo . x-scores for orthogonal component i
: t
(i)
Yo
← t(i)Yo /
(
t
(i)
Yo
T
t
(i)
Yo
)
. Normalize t(i)Yo
p
(i)
Yo
← XT t(i)Yo . x-loadings for component i: a least-squares fit of X to t
(i)
Yo
: X← X − t(i)Yop
(i)
Yo
T
. Deflate the orthogonal component out of X
end for

Algorithm  o-pls, Part 
for all i ∈ {1, . . . , aXo} do . osc on Y
: U ← YC
Q← Y TU
(
U TU
)−1
: KXo ←Q−CCTQ . Q, orthogonalized to C: heart of osc
Subtract out most significant component of KXo from Y :
: CXoSXoW
T
Xo
= KXo . Compact svd of KXo
c
(i)
Xo
← the first column of CXo
: u
(i)
Xo
← Y c(i)Xo . y-scores for orthogonal component i
u
(i)
Xo
← u(i)Xo/
(
u
(i)
Xo
T
u
(i)
Xo
)
. Normalize u(i)Xo
q
(i)
Xo
← Y Tu(i)Xo . y-loadings for component i: a least-squares fit of Y to u
(i)
Xo
:
Y ← Y −u(i)Xoq
(i)
Xo
T
. Deflate the orthogonal component out of Y
end for
:
T ← XW . Final ree¨valuation of the scores and loadings
P← XTT
(
T TT
)−1
: U ← YC
Q← Y TU
(
U TU
)−1
. Combine orthogonal components into matrices
: WYo ←
[
w
(1)
Yo
| . . . |w(aYo )Yo
]
PYo ←
[
p
(1)
Yo
| . . . |p(aYo )Yo
]
QYo ←
[
q
(1)
Yo
| . . . |q(aYo )Yo
]
: CXo ←
[
c
(1)
Xo
| . . . |c(aXo )Xo
]
TXo ←
[
t
(1)
Xo
| . . . |t(aXo )Xo
]
UXo ←
[
u
(1)
Xo
| . . . |u(aXo )Xo
]
:
BU→T =
(
U TU
)−1
U TT . Regressions are least-squares fits of the scores
: BT→U =
(
T TT
)−1
T TU

.. on-pls and future directions
Finally, the ideas developed in o-pls and o-pls can be extended even further. The
flexible nature of o-pls, combined with its completely symmetric treatment of
both the X and Y data blocks leads to a direct extension of the method to any
number of blocks: on-pls []. In on-pls, each block is decomposed into a pre-
dictive part, which takes into account correlations with every other block, and an
orthogonal part, defined relative to the predictive part, just as in o-pls. on-pls
has not yet been widely used, due to its novelty, but it offers a promising new
direction for analysis of multi-block biological data. Finally, post-processing ap-
proaches similar to ones developed for o-pls [–] may be useful extensions of
on-pls as well.


Chapter
Molecular dynamics studies of the
alloreactive T cell response
Adapted with permission from Wolfson, M. Y., Nam, K., and Chakraborty, A.K.
“The effect of mutations on the alloreactive T cell receptor/peptide-mhc interface
structure: a molecular dynamics study,” The Journal of Physical Chemistry B. June
, . Copyright © , American Chemical Society.
. Summary
T cells orchestrate adaptive, pathogen-specific immune responses. T cells have
a surface receptor (called tcr) whose ligands are complexes (pmhcs) of peptides
(derived from pathogens or host proteins) and major histocompatibility complex
proteins (mhcs). mhc proteins vary between hosts. During organ transplants, host
tcrs interact with peptides present in complex with genetically different mhcs.
This usually causes a vigorous immune response—alloreactivity. Studies of al-
loreactive protein interactions have yielded results that present a puzzle. Some
crystallographic studies concluded that the alloreactive tcr/mhc interface is es-
sentially unaffected by changing the tcr peptide-binding region, suggesting that

the peptide does not influence the interface. Another biochemical study concluded
from mutation data that different peptides can alter the binding interface with the
same tcr. To explore the origin of this puzzle, we used molecular dynamics sim-
ulations to study the dependence of the tcr/pmhc interface on changes in both
the peptide and the tcr. Our simulations show that the footprint of the tcr on
the pmhc is insensitive to mutations of the tcr peptide-binding loops, but pep-
tide mutations can make multiple local changes to tcr/pmhc contacts. Therefore,
our results demonstrate that the structural and mutation data do not conflict and
reveal how subtle, but important, characteristics of the alloreactive tcr/pmhc in-
terface are influenced by the tcr and the peptide.
. Introduction
The adaptive immune system enables higher organisms, like humans, to protect
themselves with pathogen-specific responses against a diverse and evolving world
of microbes. T lymphocytes (T cells) are key orchestrators of the adaptive immune
response. To perform their functions, they must be activated. Activation is pred-
icated on sufficiently strong binding of a T cell’s antigen receptor (T cell receptor,
tcr) to a ligand. The ligand consists of a short peptide fragment held in the cleft
of a membrane-bound major histocompatibility complex protein (mhc) displayed
on the surface of an antigen-presenting cell. T cell activation can lead to a variety
of effector immune functions.
Immature T cells undergo development in the thymus, where they interact with
pmhc complexes derived from the host proteome. To survive elimination during
the development process, the T cells must not interact too strongly with any of
these self-pmhc complexes (negative selection), but must bind with sufficient affin-
ity to at least one pmhc (positive selection) [–]. This selection process largely

inhibits autoimmune T cells from joining the immune system and ensures that
the surviving T cells can recognize foreign peptides presented on the host’s own
mhc molecules with extraordinary specificity [,]. Because of thymic selection,
peptides derived from the hosts’ own proteins do not produce a strong interaction,
but foreign-derived peptides do.
Sometimes, such as during organ transplantation, mature T cells encounter
pmhc complexes on cells from a genetically different (allogeneic) member of the
same species. Since mhc genes are highly polymorphic, allogeneic pmhcs (allo-
pmhcs) present previously unseen mhc surfaces to the tcrs. Furthermore, since
the most variable regions of the mhc occur along the peptide binding cleft, the
peptides presented by allo-mhcs likely differ in sequence and conformation from
the self-peptides used to train the tcr in the thymus, even though they originate
from the same proteins. Up to 10% of the T cell repertoire can cross-react with
any particular pmhc on the allogeneic cells— times as many T cells as the
0.01% of the repertoire activated during the response to a virus [–]. This
intense response, known as alloreactivity, makes organ transplantation impossible
without immuno-suppression.
Much experimental work has been dedicated to elucidating the roles and rel-
ative importance of the peptide and mhc in alloreactivity, and a large number of
these studies [–] have examined the interaction footprint—the interface be-
tween the tcr and the set of pmhc residues that come into contact with it, which
includes the peptide and the α1 and α2 helices of the mhc (Figure -). A question
of particular interest, has been the energetic and structural impact of the peptide
on an allo-pmhc/tcr footprint. The question has been actively explored by bio-
chemical mutation experiments and X-ray crystallography.
Some biochemical experiments have studied how a tcr interacts with different
peptides in the same allo-mhc. But these studies do not provide direct structural

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Figure -: The c tcr binds strongly to the allo-mhc ld, contacting a “footprint”
set of residues on the pmhc. (a) A crystal structure (pdb oi) of the variable chains
of the c tcr in complex with the peptide ql and the mhc ld shows the relative
orientation of tcr on mhc []. (b) The diagram of the tcr/pmhc footprint high-
lights ld residues that are in contact with c. A pmhc residue is considered to be
in contact with tcr if it has a non-hydrogen atom within 4.5 A˚ of a non-hygrogen
atom in a tcr residue. pmhc residues that do contact tcr are shaded with the color
of the chain(s) that they contact: magenta for Vα, cyan for Vβ, and dark blue for
both. Above the mhc, the c cdr loops are indicated in the color of the chain they
belong to: magenta for Vα, cyan for Vβ. The directionality of the protein backbone
is indicated by arrows that point from the amino terminus to the carboxy terminus.
Molecular visualizations for this figure were created with PyMol [].

data [, ]. One study, by Felix et al., concluded that peptide mutations could
have a noticeable impact on the tcr/pmhc footprint by affecting contacts between
mhc and tcr []. In the study, the authors mutated several residues along the
α-helices of a particular allo-mhc and observed the effects of those mutations on
T cell activation, in order to assess which residues were likely to contact the tcr.
The authors found that when different peptides were bound by the same allo-mhc,
different subsets of mhc residues impacted recognition, implying that the peptides
affected the tcr/mhc contacts.
Since the first complete tcr/pmhc crystal structure in  [], crystal struc-
tures have also been used to study several tcr/pmhc footprints. Many of these
footprints have been between tcr and peptide/self-mhc complexes [,–], but
structural studies have dealt with alloreactive complexes as well [,,–].
Two of these studies [, ] have made direct structural comparisons of the ef-
fects of different peptides of varying affinity on the tcr/allo-pmhc interface. A
recent crystallographic study by Colf et al. concluded that the peptide has lit-
tle impact on the footprint. The authors reached this conclusion by showing that
mutations on the cdrα peptide-recognition loop of a tcr bound to an allo-pmhc
complex did not impact the structure, despite increasing the binding affinity by
over two orders of magnitude []. Importantly, however, the study did not in-
volve mutation of the peptide itself. A more physical and chemical understanding
of the intermolecular interactions involved at the tcr/pmhc interface could shed
light on these seemingly conflicting biochemical and crystallographic results. Such
insight could also motivate further experiments.
One direct way to compare the two results is to understand a single system that
encompasses both peptide mutation and structural information. To this end, we
have performed an in silico analog of the peptide mutation experiments designed
by Felix et al. on tcr/pmhc structures obtained by Colf et al. []. Using molecular

dynamics simulations [], we analyzed atomistic models of tcr/allo-pmhc com-
plexes while independently changing both the tcr and the peptide, which allowed
us to directly compare the effects of each kind of mutation on the tcr/pmhc inter-
face. In our simulations, as in the crystallographic study, mutation of the cdrα
loop of the tcr did not induce a significant change in the tcr/allo-pmhc footprint,
compared to the significant differences between the tcr/allo-pmhc and tcr/self-
pmhc footprints. However, our simulations also showed that certain peptide muta-
tions can affect the tcr/pmhc interface. These peptide mutations not only affected
the peptide-tcr contacts, but also influenced which mhc residues came into con-
tact with tcr, even though they did not induce a change in the overall orientation
of tcr on mhc—a finding that confirms the conclusions of Felix et al. []. Our
simulations thus demonstrate that the crystallographic results and biochemical
results are not in conflict, because mutations to the cdrα loop are not necessarily
equivalent to peptide mutations. Our results highlight the potential of the peptide
to impact the tcr/pmhc interface by making local contact changes and suggest that
detailed chemical interactions at the interface between the tcr, peptide, and mhc
can all play a part in the ultimate structure of the alloreactive tcr/pmhc interface.
Our findings are consistent with an attractive model for tcr/pmhc interac-
tions in which the tcr docks over the pmhc and scans the ligand for a sufficient
number of interactions that confer the tcr/pmhc complex a sufficient lifetime
[, , , ]. If this necessary condition for recognition is met, structural
rearrangements occur to acquire enhanced affinity. The specific character of these
relatively modest rearrangements [] depends on the particular tcr/pmhc pair
under consideration.

. Methods
.. Structure preparation
The X-ray structures of the cx and mx [] complexes (pdb ids oi and el, re-
spectively) were used for the initial coordinates of all calculations. Three mutant-
peptide variants were generated from each crystal structure by removing the atoms
that corresponded to the mutation (Table .). This resulted in a total of eight
systems to simulate. Hydrogen atoms were introduced into the structures with a
stereochemical algorithm []. The protonation states of titratable residues were
assigned based on visual inspection and prior results for similar systems [–].
The structures were minimized with constraints on heavy atom positions and sol-
vated with explicit tipp [, ] water molecules in 89 A˚ rhombic dodecahedra
with periodic boundary conditions. 39 K+ ions and 37 – 38 Cl– ions were added
to each system to neutralize the total charge and simulate a 0.15 M KCl concen-
tration. The ions were placed with random initial coordinates, then subjected to
2000 steps of a Metropolis Monte Carlo simulation in order to equilibrate their
positions. After solvation, hydrogens, solvent atoms, and protein atoms were all
minimized with restraints in stages. First, hydrogens were minimized for 1000
steps without restraints, while heavy atoms were fixed. Then, only the solvent
atoms were subjected to 1000 additional steps of constrained minimization, with
force constants of 0.5 kcal/mol/A˚, while protein atoms were fixed. After that,
all atoms were unfixed, a 0.1 kcal/mol/A˚ harmonic restraint was placed on the
protein atoms, and the system was subjected to 1000 more steps of minimization.
Finally, the entire system was minimized again for 1000 steps without restraints.
The average number of atoms per system was 47,355.

.. Molecular dynamics simulations
All simulations were performed using the charmm [, ] molecular dynamics
program (version cb) with the charmm  [] force field and the cmap cor-
rection for the peptide backbone dihedrals []. The simulation protocol was in-
fluenced by previous tcr/pmhc simulations [–]. Molecular dynamics simula-
tions were performed with holomorphic constraints on the hydrogen atoms [],
which allowed the use of 2 femtosecond integration time steps. Non-bonded van
der Waals interactions were truncated at 9 A˚ using a force-switching algorithm
[]. Electrostatic terms were calculated using the Particle-Mesh Ewald summa-
tion method [], and the real-space terms were evaluated with a 9 A˚ cutoff. After
solvation and the energy minimizations described above, each system was heated
and equilibrated in several stages. First, the entire system was heated from 10 K to
300 K over 100 ps without restraints. Then a 3.0 kcal/mol/A˚ harmonic restraint
was placed on the heavy protein atoms, and the ions and solvent were equilibrated
with three repetitions of a heating and cooling cycle. The cycle ran constant-
temperature dynamics for 50 ps at 300 K, then heated the system to 450 K, ran
constant-temperature dynamics for 100 ps, cooled the system down to 300 K, then
ran another 100 ps of constant-temperature dynamics at 300 K. After the solvent
equilibration, a mass-weighted 0.75 kcal/mol/A˚ harmonic restraint was placed
on protein heavy atoms and the system was equilibrated for 100 ps with constant-
temperature dynamics. The restrained dynamics were followed with 100 ps of un-
restrained constant-temperature dynamics, and 200 ps of unrestrained constant-
temperature, constant-pressure dynamics. Simulations were then continued for
15 ns. Throughout each simulation, constant temperature was maintained with
the Nose´-Hoover thermostat [, ], and constant pressure was maintained
with the Langevin piston method [].

Table .: Lower-affinity peptide mutants are good candidates for simulation.
Peptidea Sequence tcr/pmhc Ka
(
M−1
)
b Reference
ql QLSPFPFDL 1.0− 2.0 ·10 []
ql-a QLSPFAFDL 2.0 ·10 []
pca -LSPFPFDL 2.0 ·10 []
pca-a -LSPFAFDL 1.6 ·10 []
a In order to assess the impact of peptide mutations on the tcr/pmhc footprint, we
chose to simulate the c/ql-ld system with several lower-affinity peptide vari-
ants. The table lists sequences and binding affinities of these peptides. The mu-
tants were chosen to impact the binding affinity by at least a factor of , so as to
not simulate “null” mutations.
b Binding affinities were obtained from solution measurements of peptide on ld,
presented to c.
. Results
.. Alloreactive model
The alloreactive model used in our simulations is based on the murine c tcr. T
cells containing this tcr were found in a mouse—whose own mhc molecules ex-
pressed the kb-haplotype—injected with cells whose mhcs had the ldhaplotype
[,]. Thus, c tcrs recognize foreign and self-peptides on the kb self-mhc and
also bind strongly to peptides presented on the ld allo-mhc (Figure -). Crystallo-
graphic experiments by Colf et al. [] have obtained the structure of the variable
part of a c tcr in contact with a peptide (ql; see Table . for sequence) held
in the cleft of a stabilized portion of ld (α1/α2 domains, residues  –  of the
heavy chain). The crystal structure of the same ligand bound to m, a mutant of
c with even higher affinity for ql/ld, was also obtained. The only difference
in sequence between c and m occurs in residues  –  of the cdrα loop,
which is changed from the sequence GFASA in c to the sequence HQGRY in m.
Despite the -fold change in affinity for the ligand caused by this mutation, it

had no significant impact on the tcr/pmhc footprint, especially when compared to
the structural difference between the c/ql-ld structure and previously-obtained
c/kb self-pmhc structures [,]. This result led Colf et al. to conclude that the
peptide did not play an important structural role in the footprint because, even
though interactions between the peptide and tcr had significantly changed, the
footprint had not.
.. Molecular dynamics simulations
To study the effect of both tcr and peptide mutation on the tcr/pmhc footprint,
we performed molecular dynamics simulations on a total of eight systems. For
the peptide mutants, we used four peptides (Table .), including ql. The three
additional peptides were derived from ql by independently introducing two mu-
tations: deletion of the terminal glutamine, and mutation of the carboxy-proximal
proline to an alanine. These mutations were chosen for their ability to noticeably
affect the binding affinity of the peptide for c [,]. Each of the four pmhcs
was simulated with both c and m tcr, with the m simulations intended to test
the effect of tcr mutation. The simulated systems are summarized in Table .,
along with their identifying abbreviations.
Since the peptide mutations involved only removal of atoms, the initial coor-
dinates of the mutant peptides were the same as the crystal coordinates of ql,
except for the deleted atoms. The molecular dynamics simulations were carried
out for 15 ns, and coordinates were saved at every 2 ps for analysis. Energetic
and structural properties of the systems were calculated by averaging over the last
5 ns of the trajectories, after the systems had reached equilibrated states. Equi-
libration was determined by a consistent plateau in the rmsd (root-mean-square
deviations) of the backbone coordinates from the crystal structure (Supplemen-
tal Figure A-). The binding free energy of the m tcr for pmhc was calculated

Table .: For clarity and conciseness, we use abbreviations to refer to the
tcr/pmhc systems discussed in this article.
Peptide tcr mhc Source Abbrev.a
ql c ld dynamics cp
m ld dynamics mp
c ld structure cx
m ld structure mx
ql-a c ld dynamics ca
m ld dynamics ma
pca c ld dynamics cp
m ld dynamics mp
pca-a c ld dynamics ca
m ld dynamics ma
siyr c kb dynamics csk
c kb structure csx
a The abbreviation code describes the distinguishing features of a system with
three characters. For the ld simulations, the first character describes the tcr in-
volved: “C” for c, “M” for m. The second character describes how many amino
acids are in the peptide: “” for ql and its mutants, “” for pca and its mutants.
The third character describes the mutant variation if the abbreviation refers to the
simulated structure: “P” for the original amino acids with proline at position  or
, ql and pca, “A” for the alanine-mutants ql-a and pca-a. The third char-
acter can also be “X,” which is a special case indicating that the abbreviation refers
to a crystal structure. Finally, the kb systems are named in a manner to mimic con-
sistency with the ld systems: “C” for c, “S” for the siyr peptide, “K” for kb, and
“X” for the crystal structure.
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Figure -: Average structures of the tcr/pmhc footprints compare the effects of
tcr, peptide, and pmhc changes. The comparison highlights the ability of the sim-
ulations to reproduce qualitative experimental results. The average structures are
aligned via their mhc backbone atoms to allow comparisons between tcr loop dis-
placement and tcr orientation. The differences between the two structures are
most noticeable in (c), and least pronounced in (a), in agreement with experimen-
tal results. (b), which highlights differences from peptide mutation, shows differ-
ences that lie in between the two extremes. The average structures were obtained
from the 5 ns of the trajectories, with rotation and translation removed. Molecular
visualizations for this figure were created with vmd [].
to be stronger (more negative) than that of c (Supplemental Table A.), which
corresponds qualitatively to experimental binding affinity measurements [].
To provide more points of reference, a model of the c/kb system was also sim-
ulated. The resolution of the crystal structure referenced by Colf et al., originally
obtained by Garcia et al. [], was not high enough for consistent simulations. In-
stead, a related structure, which replaced the original dev self-peptide with the
superagonist siyr peptide, was used []. This structure had a higher resolution,
yet differed little (rmsd 0.92 A˚ for Cα atoms) from the original c/kb/dev struc-
ture and could therefore serve as an approximate model.

.. Average structures from the dynamics highlight the overall
effect of peptide mutation
In order to evaluate the qualitative effects of peptide mutation, we calculated
average tcr/pmhc structures from each trajectory by taking the mean position
of each atom during the last 5 ns of the trajectory. Figure - displays some of
these average structures superimposed on one another for comparison. The struc-
tures in each part of the figure are aligned along their mhc backbone atoms to
highlight differences in tcr loop position and tcr/mhc orientation. Figure - is
designed to show the effect of tcr mutation (Figure -a), the effect of peptide
mutation (Figure -b), and the effect of switching from self-pmhc to allo-pmhc
(Figure -c). Looking from Figure -a to Figure -c, the differences between
the structures in each pair increase. In Figure -a, the qualitative features Colf
et al. found are reproduced: the overall orientation of both tcrs is nearly identi-
cal, [] despite a few minor loop rearrangements, leading to an average backbone
rmsd of 2.7 A˚ for the loops. By stark contrast, in Figure -c, almost all of the
tcr loops have significantly different average positions, with an average backbone
rmsd of 3.5 A˚ [], and it is clear that c binds to the different pmhcs at differ-
ent angles. Figure -a and Figure -c together demonstrate that our simulations
retain qualitative similarity to the crystallographers’ finding that cdr loop mu-
tation is insignificant, especially compared to the differences between self- and
allo-pmhc []. Figure -b shows how the effects of peptide mutation compare
with the two “extremes” of Figure -a (no effect) and Figure -c (drastic effect).
The two peptide mutant systems shown in this subfigure, ca and cp, exhibit the
greatest difference from one another among all choices of peptide mutants for a
given tcr, highlighting the maximum observed extent of peptide mutation. Com-
paring ca to cp shows that, although there is no global rearrangement of binding
orientation, as in Figure -c, there are many differences between the conforma-

tions of the c cdr loops, and the differences are distributed throughout most
of the cdr loops, yielding an average backbone rmsd of 3.4 A˚. Every loop except
cdrα exhibits a noticeable difference between the two structures. These unique
loop conformations lead to significantly different tcr/pmhc contacts. In particu-
lar, the most significant differences are seen in the cdr loops, which contact the
peptide directly. The peptides, however, are not adopting vastly different confor-
mations (backbone rmsd 1.9 A˚). This result suggests that the peptides interact with
the tcr in a highly dissimilar manner despite their relatively similar orientation
and that mutation can affect the tcr/pmhc contacts through a complex interplay
of altered interactions between the tcr and the bound pmhc.
.. tcr/pmhc contact distributions allow quantitative compar-
ison of the effects of mutation
To measure the impact of peptide mutations on the footprint, we computed the
number of contacts that each pmhc residue makes with tcr and averaged these
quantities over the structures obtained during the last 5 ns of simulation. We de-
fined any two residues to be in contact when a non-hydrogen atom in one residue
was within 4.5 A˚ of a non-hydrogen atom in the other residue. This average-
contact approach qualitatively differs from analyzing any single “representative”
structure taken from the simulation trajectory, since a single structure may not ac-
curately represent the overall ensemble of structures well enough, especially when
examining the contact footprint. Thus, an analysis based on a single structure
would likely suffer from ambiguities in interpreting the results.
The result of the average contact calculations, shown in Figure - and Fig-
ure -, is a picture of the interaction footprints as functions of pmhc sequence. In
each plot, the ordinate lists the positional indices and amino acid abbreviations for
the residues that constitute a particular segment of the pmhc—either the α1 helix
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Figure -: mhc/tcr contact distributions show a quantitative description of the
tcr/pmhc footprint. The figure compares the crystal structure footprints to their
corresponding simulations in order to establish the accuracy of the simulations.
In general, the simulations reproduce the result that mutation of the tcr does not
make widespread changes to the footprint. The ordinate axes list the residue index
and single-letter amino acid abbreviation for the residues of the mhc α1 and α2
helices. For the simulations (cp and mp), the length of each bar represents how
many contacts, on average, that mhc residue made with any tcr residue during
the last 5 ns of the dynamics trajectory. For the crystal structure data (cx and
mx), the length of a bar represents the exact number of contacts observed in that
structure. Two residues were defined to be in contact if a non-hydrogen atom in
one residue was within 4.5 A˚ of a non-hydrogen atom within another. S.e.m. error
for each bar length was calculated but is too small to be visible.
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Figure -: Peptide mutation can induce local tcr/mhc contact changes. mhc/tcr
contact distributions of peptide-mutant systems show the effects of peptide muta-
tion on the interface. Some of these effects are significant: the ca distribution is
noticeably different from the cp distribution. The ordinate axes list the residue
index and single-letter amino acid abbreviation for the residues of the mhc α1 and
α2 helices. The length of each bar represents how many contacts, on average, that
mhc residue made with any tcr residue during the last 5 ns of the dynamics tra-
jectory. Contacts were defined the same way as Figure -. S.e.m. error for each
bar length was calculated but is too small to be visible.

or the α2 helix. Around each point, which represents an individual pmhc residue, a
group of bars is clustered. The set of all bars of a single color represents a particu-
lar tcr/pmhc system, as described by the legend and Table ., and the length of a
bar represents the average number of contacts that a pmhc residue made with tcr.
Figure - shows the effect of peptide mutation on the c footprint by comparing
all simulated systems that involve the binding of c tcr to different peptides: cp,
ca, cp, and ca, respectively. Figure - serves as a control by comparing the
footprints of the c and m crystal structures (cx, mx) with their correspond-
ing simulations (cp, mp). The control set provides two methods of testing the
simulations against experimental results, showing () how well the simulations
reproduce the experimental conclusions that mutation from c to m does not
have a significant effect on the footprint, and () how similar the footprints gener-
ated by the simulations are to their experimental counterparts. To be numerically
significant, any changes observed from peptide mutation would have to be larger
than the differences between crystal structures and their simulation counterparts,
and also larger than the differences between the c and m tcr simulations.
Figure - directly shows how peptide mutation changes local contacts be-
tween mhc residues and tcr in several locations throughout the footprint, in direct
support of the findings of Felix et al. [], that peptide mutations can rearrange the
finely-paired contacts between tcr and mhc. For a more quantitative comparison
of the footprints, we present a single system’s footprint (the set of all bars of the
same color) as a discrete “distribution” of contacts over the sequence of the pmhc.
The distributions of different systems can be compared segment-by-segment by
their “means,” r¯c, shown in Figure -. The r¯cs are calculated as weighted averages
r¯c(A;S) =
∑
r∈S
c(r)r∑
r∈S
c(r)
, (.)
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Figure -: The changes in tcr/mhc contacts upon peptide mutation from cp
to ca are numerically significant. The values of r¯c for each system are plotted
above on the same axes for comparison. r¯c represents the “center of mass” of the
contact distributions, and the difference induced in r¯c by peptide mutation from
cp to ca is clearly bigger than the difference between any systems in the Control
Group. In between the r¯c axes, a color-coded picture of the contact distributions
in Figure - and Figure - is shown, in order to provide a qualitative picture of
“contact mass”: the more brightly colored a particular square is, the more contacts
with tcr it makes. Errors signified by error bars emanating from the circular data
points are in s.e.m., except for the crystallographic cx and mx systems.

where S ∈ {α1,α2,pep} is a label for a pmhc segment (either the α1 helix, the α2 he-
lix, or the peptide) of a tcr/pmhc system A, r is the sequence number of a residue
in S (denoted along the ordinate), and c(r) is the average number of contacts that
residue r makes with tcr (the length of the bar at position r that corresponds to
system A in Figure - and Figure -). Thus, r¯c(A;S) represents the average po-
sition in the sequence where the tcr contact distribution for pmhc segment S is
centered in system A, i.e. the contact center of mass. Differences between the
means of two distributions representing different systems reflect underlying dif-
ferences between the tcr/pmhc contact distributions of those systems (Figure -),
and we will use the notation ∆r¯c(A1 −A2;S) , |r¯c(A1;S)− r¯c(A2;S)| to refer to these
differences throughout the paper.
.. Mutations to the cdrα loop of the tcr do not produce sig-
nificant changes to the footprint
To verify the predictive quality of the simulations, we first examined how well they
reproduce the experimental result that cdr mutations do not significantly alter
the footprint []. Figure - and Figure - compare the contact distributions
and r¯cs of cp to mp, and cx to mx—an intra-method, inter-tcr comparison—to
assess the effect of the tcr mutation (c→m) on tcr/mhc contacts. The contact
distributions of the crystallographic cx and mx systems are very similar to one
another, except for a few stray contacts in mx near the ends of the helices and two
contacts with Arg75 of the mhc, which are only present in the cx structure (Fig-
ure -). Like their crystallographic counterparts, mp and cp are also similar to
one another, as reflected by the small difference in their r¯cs (Figure -). However,
mp has approximately one more average tcr contact than cp in several places
where mhc/tcr contacts already exist in cp. The additional average contacts are
distributed almost evenly throughout the entire contact interface. Due to the nor-

malization applied in Eq. ., this difference is not reflected in the r¯c(mp; {α1,α2})
values, and therefore, no significant shift is observed in the location of the foot-
print on the mhc. The even distribution of additional contacts suggests that m
tcr interacts strongly with the pmhc. This is consistent with the experimental
finding that the m tcr has a higher affinity for the ld-ql ligand [] and with
the computed binding free energies reported in Supplemental Table A..
As a further test of quality, we compare the ql simulations (cp and mp) to
their corresponding crystal structures (cx and mx)—the only direct experimen-
tal comparison available—in the bottom of Figure -. This inter-method, intra-
tcr comparison yields larger differences in r¯c between simulation and experiment
than the previous comparison, especially for the α1 helix. The differences may
reflect the large numbers of crystal contacts (476 crystal contacts for cx and 
for mx), that are present only in the crystal structures and are absent in our sim-
ulations. Further analysis shows that, in the α1 helix, 74% of ∆r¯c(cp −cx;α1) is
due to the two tcr contacts with residue Arg62 on the α1 helix of the mhc which
develop in the cp simulation, but are absent in the cx structure. Other contact
patterns are mostly conserved between simulation and experiment. Since such a
large part of the difference can be accounted for by only one new contact loca-
tion, the difference in r¯cs does not reflect the widespread shifts in pmhc contact
locations that would accompany a significant change in the footprint. Although
the inter-method ∆r¯c(mx −mp;α1) is larger than ∆r¯c(cx −cp;α1), and both are
relatively large, they are still smaller than the largest ∆r¯c obtained from peptide
mutation and therefore do not affect qualitative conclusions about its potential
effects.
The smaller size of both of the intra-method, inter-tcr comparison ∆r¯cs, rela-
tive to the inter-method, intra-tcr ∆r¯cs, suggests that the simulations and crystal
structures might have systematic, localized shifts from one another. Such system-

atic shifts may be caused, for example, by the absence of crystal contacts in the
simulations. The two comparisons, taken together, suggest that despite some lo-
calized differences with the crystal structures, our simulations are consistent with
the experimental result that mutation of the c cdrα loop does not induce signif-
icant perturbations in tcr/mhc contacts with ql-ld.
.. Mutations to the shortened antigenic peptide produce no-
ticeable, local changes to tcr/mhc contacts
Among all the peptide mutant systems tested, two (cp and ca) show the largest
shifts in r¯c values, larger than any other pair of systems with the same tcr by at
least a factor of two (Figure -). The exact r¯c values that underlie these differences
are shown in Supplemental Table A..
Unlike the case of tcr mutation, the simple creation or annihilation of a single
mhc/tcr contact cannot account for the large shift in r¯c. Rather, the shift is caused
by the rearrangement of several contacts and an overall shift in the contact distri-
butions of ca and cp to opposite ends of the sequence (relative to the wild-type
cp). This can be seen clearly in Figure -b, where the cdr and cdr loops for
both Vα and Vβ have noticeably different average conformations in ca than they
do in cp.
We also determined how widely distributed along the mhc the differences be-
tween cp and ca are (Figure -). When comparing two footprints, we define a
pmhc site as “changed” if it has 1.0 or more average contacts in one footprint, and
0.5 average contacts or less in the other. This choice of cutoff values is reasonable,
as a pmhc residue with less than 0.5 average tcr contacts makes no contact with
tcr more than half the time, but a pmhc residue with 1.0 average tcr contacts is
in contact with the tcr on average once every time step in the trajectory. Using
the above definition of change to compare ca to cp yields 8 changed sites out of

22, while comparing cp to cx or cp to mp yields only 4 out of 21 sites. The re-
sults are not very sensitive to changes of the cutoff values: if either parameter were
varied by up to 10% in either direction, only two changed sites would lose their
label, and in both cases, it is because the high value is very close to 1.0, and would
cease to qualify as a contact if the upper threshold were raised to 1.1. The compar-
atively large number of changed sites demonstrates that differences between the
ca and cp footprint are widely distributed and represent changes throughout
the footprint.
Figure - also shows that the wild-type cp contact distributions are centered
between those of the cp and ca systems for both mhc helices. Thus, relative
to the original, wild-type footprint, the lone deletion (cp) and deletion-with-
mutation (ca) have opposite, non-additive effects, possibly due to how greatly
deletion can affect the space available to the peptide. Taken as a whole, these ef-
fects are relatively localized to the tcr-mhc interface, and they do not involve the
kind of structural rearrangement of tcr/mhc orientation observed when compar-
ing the allo c/ql-ld(cp) to c/siyr-kb (csk) (Figure -c), nor do they involve
large rearrangement of the cdr loops themselves. This perspective is consistent
with assessments of tcr/pmhc interfaces that highlight the relative inflexibility of
the cdr loops [,]. Nevertheless, it is clear that mutation of the antigenic pep-
tide, unlike mutation of the cdrα, can induce noticeable rearrangement of local
contacts in the footprint.
Most importantly, these peptide mutation results are completely consistent
with the findings of Felix et. al [], which implied that changing the peptide can
make changes to contacts between mhc and tcr throughout the footprint. They
are also consistent with a previous crystallographic study of dissimilar peptides
in the same tcr/allo-mhc complex []. Performing r¯c calculations on the crystal
structures compared in that study showed that the contact distributions of the dif-

ferent peptide mutants differed by as much as two residue positions—much more
than cx differed from mx (Supplemental Table A.).
Recent crystal structures obtained by MacDonald et. al [] show the lc
tcr in complex with different peptides in the same allo-mhc. In both cases, the
tcr produces a remarkably similar footprint on the substrate. In this situation,
however, no residues were removed from the peptide, so the physical impact of
mutation was not as severe, despite several sequence differences between the two
peptides. Such results indicate that not all kinds of peptide mutation are equiva-
lent: while allopeptide mutations can have an impact on the tcr/pmhc footprint,
this is not necessarily the case for a particular tcr/pmhc pair and a particular
mutation—in the end, the specific interplay of tcr, peptide, and mhc interactions
determines the ultimate interface structure.
.. Peptide mutations can impact the topology of the interface
by changing the ratio of tcr Vα and Vβ chain contacts
A particular feature of the c contact distributions is that the ranking of r¯c values
for the α1 helix is the inverse of the ranking for the α2 helix. That is, r¯c(ca;α1) >
r¯c(cp;α1), but r¯c(ca;α2) < r¯c(cp;α2) (Figure -). Since the sequence of the mhc
α helices is organized in such a way that the N-terminus of one helix is close in
space to the C-terminus of the other helix and vice versa (Figure -), what appears
as shifts in opposite directions along the sequence actually corresponds to a shift
of the contact footprints in the same direction in space. Specifically, the shifts
indicate that for cp, more tcr contacts occur on the part of the mhc near the
N-terminus of the peptide (the left end in Figure -b), while for ca, more tcr
contacts occur on the part of the mhc near the C-terminus of the peptide (the right
end in Figure -b). The more space available to -mer peptides may allow this
“rocking” flexibility, as is discussed in the following section.

Table .: Peptide mutation can affect the ratio of Vβ/Vα contacts with pmhc.
System Avg. Vα/pmhc cont. Avg. Vβ/pmhc cont. Ratio Vβ/Vα cont.a
cp 23.57± 0.06 16.91± 0.05 0.71± 0.08
ca 23.20± 0.05 15.89± 0.07 0.68± 0.09
cp 26.54± 0.06 21.17± 0.05 0.79± 0.08
ca 15.41± 0.06 22.55± 0.06 1.46± 0.08
mp 29.85± 0.05 19.03± 0.07 0.63± 0.09
cx 25 23 0.92
mx 27 22 0.81
a In ca, tcr contacts with pmhc are biased toward the Vα chain, while in cp,
they are biased toward the Vβ chain. The difference between average Vα contacts
between ca and cp is larger than any of the differences obtained from comparing
corresponding simulation and crystal structure data, or from comparing cp to
mp. Errors reported are s.e.m.
From the diagram of the footprint in Figure -b, it is clear that the Vα chain
of the tcr is oriented closer to the C-terminal end of the α2 mhc helix (on the
right in the figure), and the Vβ chain of the tcr is oriented closer to the C-terminal
end of the α1 helix (on the left in the figure). Combining this structural knowledge
with the contact data discussed above, we expect that cp would contain more mhc
contacts with Vα, and ca would contain more mhc-Vβ contacts. In other words,
the change from cp to ca would increase the ratio of Vβ to Vα contacts. Table .
shows that this is the case. In cp, ld makes  contacts with Vα and  contacts
with Vβ, while in ca, ld makes only  contacts with Vα and  contacts with Vβ.
The changes result in a shift of the Vβ/Vα ratio from . to . as cp changes
to ca. Figure - provides a structural explanation of the drop in Vα contacts,
showing that in ca, the cdrα loop tends away from the mhc, unlike in cp.
These results demonstrate how the mutation of the fifth position of the short-
ened peptide from a proline to an alanine (cp→ ca) can cause rearrangement of
the contact topology, affecting not only which mhc residues come into contact with
tcr, but also which tcr residues contact the mhc.

.. Mutations to the -mer peptide produce less contact rear-
rangement than mutations to the -mer peptide
By looking at all four peptide variants together, we can compare the relative impact
of the mutation of the Ala6/5 residue on the footprint in both the -mer and -mer
peptides. When we compare ∆r¯c(ca −cp; {α1,α2}) to ∆r¯c(ca −cp; {α1,α2}), it is
clear that the footprint is significantly more sensitive to mutation at the Ala5 posi-
tion of the -mer peptide than it is to mutation at the corresponding Ala6 position
of the -mer peptide. While mutation of the -mer peptide does change contacts
throughout the footprint, these changes do not affect the values of r¯c(cp; {α1,α2})
or r¯c(ca; {α1,α2}) more than inherent differences between crystal structure and
simulation. Thus, although they may be due to underlying differences in the con-
tact interface, these differences are not large enough to be seen as significant.
The shorter peptide evidently allows more freedom for the α helices—and
thereby the entire footprint—to rearrange in response to a mutation in the center
of the peptide. Despite such rearrangement, the mutation seems to have a simi-
lar effect on tcr binding in both the -mer and -mer peptide systems, lowering
the tcr/pmhc affinity by two orders of magnitude (Table .). This lack of corre-
lation between binding affinity changes and structural rearrangement may seem
counterintuitive, but it is in fact consistent with other results that describe sets
of nearly identical tcr/pmhc crystal structures with highly varying tcr binding
affinities [].
The structural distinction that the footprint makes between mutations to the
shortened and full-length peptide suggests that tcr and allo-pmhc have a compli-
cated interaction landscape at their interface and therefore can respond to subtle
changes in unique ways.

. Discussion
The intent of our study has been to provide insight into the structural impact of
peptide mutations on the alloreactive tcr/pmhc interface by comparing atomistic
models of systems that have not yet been crystallized. In our simulations, mutation
of the tcr’s cdrα loop did not induce significant rearrangement of the tcr/mhc
contacts, but certain mutations of the peptide made noticeable changes to local
contacts throughout the tcr/pmhc interface.
Our results contribute to a large body of work aimed at elucidating the na-
ture of the c tcr alloreactive response in particular and alloreactive responses in
general. That work has yielded two differing pictures of the peptide’s structural
influence on the tcr/pmhc footprint: a peptide-centric model [, , , ], in
which the peptide plays an important role in determining the footprint, and an
mhc-centric model [, , , ], in which the footprint is determined by the
mhc, with the peptide having virtually no effect. These views are sometimes sim-
plified as a “tail wagging the dog/dog wagging the tail” debate, with the dog being
the mhc and the tail being the peptide. Some experimental results, such as the
mhc mutation experiments of Felix et al. [] and the alanine-substitution work
of Conolly et al. [, ], have been cited as support for the peptide-centric idea.
Other experiments, specifically the work of Colf et al. [], have been explained as
support for the mhc-centric model.
Our findings serve as a synthesis and explanation of these apparently conflict-
ing views. We show that, while cdr mutations do not necessarily influence the
alloreactive contact footprint, peptide mutation, by contrast, can have an influ-
ence. The difference between the observed effects of these two kinds of muta-
tions highlights the difference between influencing the tcr/peptide interactions
by changing only the tcr’s cdr residues and mutating the peptide itself, which is
a more direct way to test the peptide-centric model. Our simulations reveal that

the two experimental approaches are not equivalent, as mutations to the peptide
can directly impact the mhc helices and thus affect the chemical surface to which
the tcr binds in ways that mutations of the cdr loops cannot. However, even in
the cases where we found that peptide mutations broadly affected the footprint,
these effects were relatively localized compared to the difference between self- and
allo-mhc footprints made by the c tcr [].
. Conclusions
We thus predict that both mhc and peptide have a direct impact in determining the
tcr/allo-pmhc footprint, with the peptide being able to “edit” the specific contacts
after initial contact between the tcr and pmhc. One mechanism for this multilevel
impact may involve the tcr “reading” the pmhc ligand in search of enough suf-
ficiently favorable interactions. If enough interactions exist and the tcr/pmhc
complex survives long enough, modest, specific rearrangements of the interface
residues would occur to maximize the affinity [,]. This mechanism is consis-
tent with our findings and is also consistent with diverse other findings, including
those of MacDonald et al. [], because rearrangements after the initial scanning
induced by the peptide could produce a similar final structure in initially different
pmhc landscapes.
Looking forward, we believe that free energy simulations of tcr/allo-pmhc
similar to those previously performed for tcr/self-pmhc [–] would be infor-
mative, providing more detailed free energetic data, such as a systematic compar-
ison of the relative contributions of peptide mutation and mhc changes on the tcr
binding affinity. Most importantly, testing the predictions made by our simulations
by obtaining crystal structures of the cp and ca systems (or some analogues) and
performing analysis similar to our own with these structures will shed more light

on the interplay between peptide and mhc on alloreactivity. We hope that our
study will motivate such experiments.

Chapter
Dimensionality reduction techniques
and visualizations for phenotype
analyses of adoptive T-cell transfer
melanoma therapy
. Summary
Adoptive cell transfer therapy holds promise in cancer treatment. One of the key
issues inhibiting its effectiveness is the ready identification of specific phenotypes
responsible for anti-cancer activity. New multicolor facs technology allows identi-
fying cell types with many more surface markers, but this increases the dimension-
ality of the space and makes phenotype distributions more difficult to visualize.
To enable visualization and analysis of the new, higher dimensional datasets, we
applied techniques from multivariate analysis and developed unique visualiza-
tion techniques to present the multidimensional data in a comprehensible format.
This thesis chapter outlines and explains these methods and their application to
two specific datasets: a in vivo set of T cells subject to different stimulation proto-

cols, and a in vivo set of ten patients subject to act. We found that our methods
could redisplay the data in useful ways to identify several global trends, pick out
specifically relevant phenotypes, and detect outliers. We hope that our insights
can direct future stages of experiments to understand and improve this promising
medical technology.
. Introduction
Adoptive cell transfer (act) therapy is a promising technique for treatment of
metastatic melanoma []. During act, cancer-specific T cells are activated and
expanded ex vivo. The patient’s own T cells are depleted, and the activated cells are
transfered as a replacement. Many approaches exist for generating and activating
the cancer-specific T cells before infusion. Regardless of the approach, the phe-
notype distribution of the transfer population before and after transfer strongly
affects the result of the treatment []. Understanding which phenotypes lead to
improved patient outcomes is therefore essential to the growth and development
of act.
T cell phenotypes are most commonly measured with facs immunotyping of
the surface markers expressed on the surface of a population of cells. Early im-
munotyping implementations allowed simultaneous detection of only one or two
cell surface markers. The restricted number of simultaneous measurements re-
sulted in datasets that were easy to visualize directly in  –  dimensions. However,
this data could not measure higher-order correlations between surface marker lev-
els.
Recent advances in multicolor facs immunotyping have enabled the simulta-
neous detection of five or more surface markers on the same cell []. The higher-
dimensional data provide a much richer description of the phenotypes present in

a cell population, but they are difficult to visualize and interpret. Attempts to
visualize the data directly, such as color-coded scatter plots [], suffer from a
lack of clarity: even if all five phenotypes are represented with some combination
of position and color, direct visual comparison of five-dimensional sets of data is
elusive []. The recent work of Nolan and coworkers [] provides a power-
ful technique for handling wide-spread variability in size and granularity of cells
in facs measurements and allows side-by-side comparison of high-throughput re-
sults from many conditions, but it does not address the question of interpreting
the resulting multi-dimensional space of surface markers and phenotypes.
Given the difficulty of direct visualization, understanding the data requires
analyses that extract or highlight relevant qualitative features. Dimensionality
reduction and correlation analyses are powerful techniques for addressing specif-
ically these types of problems, especially when combined with appropriate visu-
alizations. They identify qualitative features in the data through calculation of
similarity measures and projection of the data into revealing subspaces of lower
dimension.
This thesis chapter describes the application of statistical and heuristic tech-
niques for dimensionality reduction, comparison, and visualization of complex,
high-dimensional facs data of act cells obtained by our collaborators at ucla
[, ]. The data come from two datasets: a collection of in vitro phenotype
measurements made on engineered T cells subjected to four activation protocols,
and a collection of in vivo measurements made on a separate set of T cell popula-
tions adoptively transfered to a cohort of ten human patients.

. In vitro data
The biological motivation and experimental details behind the collection of the
in vitro dataset are fully described in the work of Tumeh, et al. []. Thus, the
emphasis of this work will be on the statistical modeling, and only the essential
biological detail will be described.
.. Methods
Experimental setup
Multicolor facs immunotyping was performed on cd and cd T cells subjected to
four different clinical-grade activation protocols. The four protocols resulted from
two choices of activation method (anti-cd antibody okt or anti-cd// beads)
and two choices of cytokine milieu (il- alone or il- with il-). These activation
protocols, along with their abbreviations, are described in Table ..
For each protocol, the cells were measured at five time points: , , , , and 
days after activation. At every time point, three facs experiments were performed
on the population. Each experiment measured a separate set of surface markers,
as described in Table .. The five surface markers in each set define 25 = 32
phenotypes, which come from all possible combinations of a cell having high (+) or
low (−) expression of that particular surface marker. Thus, an example phenotype
from group A would be cd25+ cd127− cd45ro+ cd44+ hla-dr−. Every phenotype
in a group is associated with a single data point for every time point and activation
protocol. This data point is a cell frequency, a fractional number between 0 and 1
representing how many of the cells on average express this phenotype. For a given
activation protocol and time point, the frequencies in each group necessarily sum
to 1.
In summary, the dataset consists of 1920 data points, as described by the equa-

Cytokine Activation
okt antibody anti-cd// beads
il- P00 P01
il- / il- P10 P11
Table .: Engineered T cells were subjected to four activation protocols, resulting
from two choices of activation method and cytokine milieu. The label given to
each protocol is shown in the table.
Group Surface Markers
A cd25 cd44 cd45ro cd127 hla-dr
B ccr5 ccr7 cd45ra cd137 pd1
C cd27 cd28 cd57 cd62l cd95
Table .: Each cell population was measured for three separate groups of five
surface markers each. Note that it is not possible to measure joint expression of
surface markers in different groups directly.
tion below:
4 protocols× 5 time points
protocol
× 3 marker groups
time point
×
32
phenotypes
marker group
× 1 data point
phenotype
= 1920 data points. (.)
Statistical analyses
The immunotyping experiments result in a wealth of data: too much to be readily
visualized directly. Dimensionality reduction and analysis are needed in order to
organize the data in a meaningful way and address important biological questions.
The analyses performed will help address two key areas: how different are the
effects of the four activation protocols on the phenotype distributions, and which
phenotypes and surface markers are the most highly variable? The more variable
a surface marker is, the more likely it is to represent an underlying biological
process.

Both of these questions can be addressed with correlation and principal compo-
nent analysis. These two related techniques describe and analyze which variables
in a dataset are changing the most, how changes in one variable tend to impact
another variable, and which subsets of variables tend to change in similar (or op-
posing) ways. The techniques can be effectively described without the details of
the mathematics, which can be found in a broad spectrum of mathematical litera-
ture [].
Fundamental to both of the analysis techniques is the notion of “variables” and
“samples.” Variables refer to a quantity that can change, such as the fraction of
cells that express a surface marker, or the concentration of a compound. Samples
refer to explicit observations of a variable. Datasets are often organized in tables,
with each column labeled by a variable and each row labeled by a sample. This
abstract assignment of variables and samples makes clear that the two notions are
labels and can be assigned in multiple ways. One could imagine turning the data
table on its side, flipping the assignment of the two terms. Such a transformation
may not always have meaning, but it is often worthwhile and allows a different
perspective on the data.
In the facs data, the straightforward approach is to label the phenotypes as
variables. The samples of the phenotype variables are then the frequencies of those
phenotypes measured under all twenty treatment and time point conditions. The
opposite label assignment is less intuitive but equally valuable. In this assignment,
the variables are the twenty measurement conditions, each specified by an activa-
tion treatment and a measurement time. The samples of the condition variable are
the frequencies of all  phenotypes measured under that condition. When both
label assignments are used with the same analysis technique, an application of that
technique is referred to for clarity as either a phenotype analysis (the variables are
phenotypes, the samples are experimental conditions) or a condition analysis (the

variables are experimental conditions, the samples are phenotype frequencies).
For either assignment of variables and samples, there is a quantity—the covari-
ance—that describes how one variable fluctuates with respect to another. If, on
average, variable A tends to go up as variable B goes up, their covariance will be
positive. If the opposite happens, the covariance will be negative. In the calcula-
tion, the samples represent the specific values of A and B used to determine this
quantity. If A = B, the covariance is the same as the variance of A.
Two examples of covariance calculations illustrate the impact of the assignment
of variables and samples. In an example phenotype covariance,
A = cd25+cd127−cd45ro+cd44+hla-dr−, and
B = cd25−cd127+cd45ro+cd44+hla-dr−.
The frequencies of both phenotypes are compared at the same time points for all
four treatment conditions (the samples), and based on their similarity, a single
covariance number is calculated that relates the two phenotype variables. Con-
versely, in a sample condition covariance, A = day /il-/okt, and B = day /il-
,il-/okt. In this formulation, the samples are the individual phenotype fre-
quencies for each of those conditions. That is, instead of comparing the levels
of two phenotypes under all measurement conditions, the comparison is now be-
tween two measurement conditions, over all phenotypes. This correlation can be
interpreted as a measure of the similarity of the phenotype frequency distributions
for the two conditions.
The larger the values of A or B are, the larger the magnitude of their covari-
ance will be, regardless of its sign. This is not always desired, for example, when
quantities are measured in different units. Another example comes in the case of
comparing measurement conditions above. When comparing phenotype distribu-

tions across measurement conditions, there is no reason to give conditions with
more variable distributions a higher covariance with other distributions: all that
is of concern is the way that two conditions’ distributions compare relative to one
another. In such cases, the covariance can be rescaled to be a number between −1
and 1. The rescaled covariance is known as the correlation, and has similar proper-
ties to the covariance except its dependence on magnitude. For a set of n variables,
n2 covariance or correlation values can be arranged into a matrix whose entry at
row i, column j represents the covariance between the ith and jth variables. This
matrix is symmetric along its diagonal, the entries of which are either the variances
of the variables (in the case of covariance) or all ones (in the case of correlation).
Two examples of a correlation matrix are shown in Figure -.
Visual inspection of the correlation and covariance matrices in Figure - can
already yield many qualitative insights into the structure of the data. For example,
for cd cells, the bottom-right corner of of the correlation matrix shows that the
phenotype distributions collected on day  are much more similar to themselves
than to any of the other distributions, regardless of treatment. Furthermore, the
data from days  –  are relatively similar to one another, and day  is unique.
We can immediately observe that experimental protocol plays a secondary role to
time in describing the collected phenotype distributions.
But correlation matrices may not always exhibit such visually distinct corre-
lated and uncorrelated groups. We must therefore extract indicators from the data
that describe the important qualitative aspects of the correlations in the data. This
extraction process is known as Principal Component Analysis (pca), and the ex-
tracted indicators are known as principal components (pcs) []. Principal com-
ponents are weighted sums of the original (manifest) variables defined by the sets
of weights (loadings) used in the sum. They are defined to be entirely uncorrelated
with one another, while simultaneously capturing as much of the variance in the

original data as possible. When used to analyze a covariance matrix, they repre-
sent correlated clusters of the most dynamic and widely changing variables; when
used to analyze correlation matrices, they represent clusters of highly correlated
variables. There are as many components as original variables, but, because each
component is designed to capture as much of the data’s variances as possible, only
the first handful tend to matter. These first few components define a subspace
onto which the data can be projected, similar to cutting through a cloud of points
with an aptly placed plane. The projection can reveal important grouping in the
data that is not visible by examining it directly. The technical details of the pca are
described in Chapter .
Finally, because the phenotypes are composed of surface markers, the total ex-
pression frequency of a surface marker is the sum of the expression frequencies
of all the phenotypes that express it. For example, if f (x) represents the total ex-
pression frequency of x at a particular measurement condition, then the following
equation holds:
f (cd25+) =
f (cd25+cd127−cd45ro−cd44−hla-dr−) +
f (cd25+cd127−cd45ro−cd44−hla-dr+) +
f (cd25+cd127−cd45ro−cd44+hla-dr−) +
f (cd25+cd127−cd45ro−cd44+hla-dr+) +
. . .
f (cd25+cd127+cd45ro+cd44+hla-dr+)
(.)
Also, because all surface markers are exclusively either high (+) or low (−), it is

clear that
f (cd25−) = 1− f (cd25+)
f (cd25+) = 1− f (cd25−).
(.)
By calculating and analyzing the expression frequencies of surface markers and
not only individual phenotypes, we can see if and how specific phenotype fluctu-
ations fit into a larger picture of surface marker fluctuations. For example, the
cd25+ cd127− cd45ro− cd44− hla-dr− phenotype may be highly expressed, with
a frequency of 0.7. We would like to know which surface markers are associated
with that high frequency. In order to do this, we calculate the total expression fre-
quencies of each of the surface markers in the phenotype. Since all the frequencies
are nonnegative, these total expression frequencies will be larger than 0.7. How-
ever, the closer a surface marker’s frequency is to 0.7, the larger the percentage of
that frequency comes from cd25+ cd127− cd45ro− cd44− hla-dr−. If, for exam-
ple, f (cd25+) = 0.72, and the other surface markers
f (cd44−) = f (cd45ro−) = f (cd127−) = f (hla-dr−) = 0.99,
it is clear that the cd25+ surface marker is the only informative part of the pheno-
type: since almost all of the cells in the sample are cd44−cd45ro−cd127−hla-dr−,
it does not matter that this highly expressed phenotype contains those surface
markers. But regarding cd25, it is clear that the cd25+ cd127− cd45ro− cd44−
hla-dr− phenotype makes up over 97% of all cd25+ cells (as opposed to only 70%
of the other surface markers). Based on such interplay between the surface marker
levels and the individual phenotypes, we can analyze general trends, such as an
increase in cd25+ cells, and also identify the specific phenotypes that are respon-
sible for those trends, such as cd25+ cd127− cd45ro− cd44− hla-dr−.

.. Results
The analysis techniques described in the Methods section were combined to extract
systematic trends in the data and present it visually in a way that highlighted the
most relevant changes.
Measurement condition correlations
In order to assess the effects of activation protocol and time on phenotype dis-
tributions, correlations between measurement conditions were calculated and are
displayed in Figure -. For this analysis, all three groups of phenotypes (96 in
total) were used as samples to compare the phenotype distributions of every pair
of experimental conditions.
The largest trend in the data is immediately visible: clustering of correlations
around days. The indication is that, for cd cells, the distributions at Day  are
unique. Then, on days , , and , the distributions are all relatively similar.
Distributions for the same day are usually more similar to one another than other
days, and activation protocol does not appear to play a large role in distinguishing
the experimental conditions for that day from one another. Finally, by day , the
population has shifted to yet another, dissimilar phenotype distribution, which is
almost invariant to the choice of activation protocol. cd cells exhibit a similar
trend, except that the day  conditions do not belong to the same “block” to which
the day  and day  conditions belong. In summary, while the activation protocol
may impact other factors, such as population size, growth rate, and cd/cd bal-
ance, it is clear that, within the separate cd and cd populations, the main factor
influencing the distribution of phenotypes is time, not activation protocol.
The second most visible conclusion is the observance of an “outlier” in the il-
/okt protocol at day . This distribution is much more similar to itself than to
any other experimental condition for cd cells, and expresses a similar uniqueness

for cd cells. This unexpected violation of the trends established by all of the other
measurement conditions leads to the conclusion that some experimental circum-
stances affected those cells in an unexpected way. Our conclusion, arrived at with
no knowledge of the specific experimental conditions, was later supported by the
experimentalists, which displays the method’s ability to successfully predict rele-
vant properties from only the data.
Thus, by simply describing the correlations between phenotype distributions
over the multiple measurement conditions, it is possible to observe global trends
in the data and identify outliers. Now that the general trends have been identi-
fied, the specifics of which phenotypes are highly expressed in which of the ex-
perimental conditions can be determined by direct examination of the phenotype
distributions for the conditions of interest, or with another visualization method,
discussed below.
Time evolution of phenotype distribution
In addition to observing global trends, it is possible to highlight specific fluctua-
tions in phenotype levels. Unfortunately, to display all of this data together would
be overwhelming. We therefore developed a technique to display what the most
important phenotypes are, given a particular facs experiment, and show which
surface markers are most closely associated with their expression. To display this
data, we have developed a new visualization technique, the “subway plot,” shown
in Figures - – -.
The subway plot, so named for its resemblance to maps of subway routes in
urban areas, shows a select subset of the phenotypes collected during a facs exper-
iment and subjected to an activation protocol. Since the first principal component
in covariance pca analyses is known to identify the most variable factors with large
weights [], the subset is determined by selecting the most variable and highly

expressed phenotypes, by selecting all phenotypes with large loadings in the first
principal component of a phenotype covariance pca. In this way, the multidimen-
sional nature of the phenotypes has been reduced to a single dimension without
sacrificing the complexity of correlations between multiple surface markers.
The subway plot shows which surface marker frequencies are influenced by a
phenotype. For every time point, each phenotype in the subset is compared to ev-
ery surface marker it expresses. Any surface markers which are sufficiently widely
expressed in the entire population and whose expression comes mostly from that
phenotype are identified with large circles as “significant.” Circles from the same
phenotype on neighboring timepoints are connected with thick lines for visual
clarity. Specifically, for a surface marker to be identified at a particular time point,
the phenotype must constitute more than 5% of the population and be responsi-
ble for more than 20% of all cells which express that surface marker. Furthermore,
there can be no more than three such markers, and the contributions of those mark-
ers must be at least 150% of the average contributions of the other markers. The
second set of criteria prevent a situation in which a phenotype makes significant
contributions to too many surface marker levels. Because of the stringent crite-
ria for significant surface marker identification, some time points are identified
with no surface markers at all. When significant markers do exist, they are further
identified by a pair of numbers (p1 × p2): expression percentages. p1 and p2 show
that the phenotype in question accounts for p1% of all cells expressing (or not ex-
pressing) the surface marker, and that p2% of all cells express this surface marker.
The corresponding expression level of that phenotype at that time point is thus
p1 × p2. Because subway plots display three-dimensional data, it is often difficult
to identify a point’s position on the (x,y) plane. For this reason, the subway plot
“grounds” each point with a line extending down to the (x,y) plane. The position
where the line meets the (x,y) plane unambiguously identifies the x and y coordi-

nates of that point. The tick marks on the line correspond to the tick marks on the
z axis at edges of the plot, unambiguously identifying its z coordinate.
The subway plots highlight the same general trends as displayed by the corre-
lation analysis: that, on the whole, time has a much larger impact on the pheno-
type distribution than activation protocol. However, the subway plots also allow
identification of specific surface markers that are commonly expressed in partic-
ular conditions. For example, in Figure -, Group C clearly highlights the broad
emergence of cd62l− cells in day . In all cases, approximately half of this popu-
lation is accounted for by the cd27− cd28+ cd62l− cd57− cd95+ phenotype. An-
other example is available in Figure -, Group B, where the subway plot shows
the clear emergence of cd45ra− cells at the - and -day time points, fueled by
the ccr5− cd45ra− ccr7− cd137− pd1− phenotype. By combining both general
trends with specific data, the subway plots allow comprehensive visualization and
comprehension of the key features in the phenotype distribution data.
. In vivo data
Like the in vitro data, the goal in analyzing the in vivo data was to identify specific
phenotypes with biologically relevant properties and to obtain a global perspective
on significant trends in the data [].
.. Methods
Experimental setup
In vivo phenotype distributions were obtained from a cohort of ten patients un-
dergoing a trial act therapy. Genetically engineered cd4+ and cd8+ T cells were
stimulated ex vivo and transfered to a cohort of ten patients. Phenotype distribu-
tions of T cells were collected from the patients’ blood at time points between 

Patient Collection Time (days)
f-      
f-     
f-        
f-     
f-        
f-        
f-       
f-       
f-   
f-   
Table .: Phenotype data was collected from each patient for up to nine time
points between  and  days after transfer. Days were grouped according to a
hierarchical clustering approach using their Euclidean distances. Data for some
patients was collected beyond  days but is not used in the analysis.
Group Surface Markers
a cd25 cd45ro cd127 hla-dr
b ccr5 ccr7 cd45ra pd1
c cd27 cd28 cd62l
Table .: In the in vivo data, each patient’s T cells were measured for three sep-
arate groups of three to four surface markers each. Note that it is not possible to
measure joint expression of surface markers in different groups directly.
and  days after transfer. The multicolor facs data generated from the in vivo
trials was similar to the in vitro data but contained three substantial differences.
First, instead of four activation protocols, the data now consisted of phenotype
distributions from ten patients. Second, each patient had more time points and
the time points were no longer the same for all patients, as shown in Table ..
Finally, the phenotypes themselves were different. They are composed of fewer
surface markers and the groupings have changed. The in vivo surface markers are
displayed in Table ..

Statistical analyses
Given the success of statistical analyses to extract qualitative information and from
the in vitro data, we extended the techniques to describe and analyze the in vivo
data. The large number of patients (as compared to the relatively few in vitro ac-
tivation protocols) meant that the subway plots developed to analyze the in vivo
data were no longer coarse enough to identify global trends: to compare ten sub-
way plots simultaneously is much more difficult than to compare four. Instead,
other methods were employed to identify relevant trends.
Specifically, phenotypes which decayed or grew very rapidly and phenotypes
which varied greatly were of biological interest. In addition to identifying particu-
lar phenotypes which exhibited interesting behavior, Principal Component Analy-
sis was used to represent the entire dataset in a reduced-dimensional space which
identified the phenotypes which corresponded most strongly with a particular pa-
tient or time point.
Finally, because of the many time points available for each patient, a regression
model was created to establish a relationship between phenotypes and the time
during which they are expressed. The regression model was developed with Partial
Least Squares Projection onto Latent Subsets (pls, also called Partial Least Squares
Regression), a statistical technique that combines pcawith least-squares regression
to produce correlated subsets of variables, a reduced-dimensional mapping, and a
regression model that is resistant to over-fitting. The time-based pls model, based
on the work of Rivet and coworkers [], provides a concrete indicator of how
strongly each phenotype is associated with early or late time points. It can also be
used to predict the age of a population of adoptively transfered T cells solely from
its phenotype distribution. The remaining technical details of the pls model are
described in Chapter .

.. Results
Outliers and inconsistent data detection
To identify global trends between patients and time points, a condition correla-
tion analysis was performed on the patient data. Its schema mimicked the in vitro
correlation analysis: the individual patients and time points were treated as vari-
ables, and correlation coefficients were calculated across variation in phenotype
expression levels. The results of the condition correlation analysis are displayed
in Figure -.
The structure of the correlations displayed in Figure - allows us to iden-
tify inconsistencies in all cd4+ T cell observations and cd8+ T cell observations
from patient f-. The cd4+ correlations show considerable cross-patient vari-
ability, which is starkly different from the globally positive correlations seen in
the cd8+ data. The variability is likely associated with the low cd4+ cell counts
obtained from patients’ blood and is therefore attributed to experimental error.
Similarly, correlations in cd8+ phenotype distributions from patient f- show a
visible contrast with data collected from the other patients. This inconsistency is
also associated with other indicators of experimental error in the data from patient
f-. Because both the cd+and f- data were associated with other indicators of
experimental error, they were discarded from further analysis.
Although the correlation analysis highlights experimental sources of error, its
ability to identify inconsistencies without prior knowledge speaks to the power
of the technique. In similar situations, it is clear that data displaying a unique
correlation pattern should be scrutinized in order to ensure that the source of the
unique pattern was not an experimental artifact.

Variability and dimensionality reduction
As with the in vitro data, it is important to identify which in vivo phenotypes vary
the most and how they change across time and patient. For this reason, a phe-
notype covariance pca and correlation pca were performed on the data. The co-
variance pca identified the most variable phenotypes and the correlation pca pro-
jected the data into reduced dimensions that displayed patient-based clusters and
identified which phenotypes discriminate best between patients. These techniques
provide powerful insight into the most substantial sources of variation in the data.
By comparing the variances of phenotypes to the magnitude of their loadings in
the first principal component of a covariance phenotype pca, Figure - displays a
clear separation of a small subset of highly varying phenotypes. Both the variance
and the first pc loading are indicators of variability. They are nearly synonymous
to some extent, as the r > 0.9 correlation coefficient indicates. However, they differ
enough to allow discrimination in the choice of variables. This is because the first
pc loading also takes into account covariance with other phenotypes to a certain
extent. Thus, a phenotype which by itself does not have a particularly high vari-
ance but covaries strongly with other variables which do have large variances may
still have a high loading in the first pc. By comparing variability with these two
metrics, Figure - is able to identify six highly varying phenotypes. In particular,
the cd27− cd28− cd62l− phenotype stands out as both the phenotype with the
largest variance and the largest pc loading.
In addition to comparing variability, pca can be used to identify the sources of
variation in the data and project it onto a subspace that is defined by those sources.
Figure - displays a biplot that summarizes a wealth of global information about
the phenotype data. A biplot is a plot specifically designed to plot the results of
a pca together []. The content is composed of two parts: a scatterplot of pca
scores and radial lines representing the pca loadings. The loadings, as described

before, are the weights that define a principal component in terms of the manifest
variables (in this case, the phenotypes). They show how the plane defined by the
two pcs is oriented in the space of the phenotypes, i.e, which phenotypes impact
the pcs, and in what way. The scores are the representation of the observations
in terms of the principal components. Each point on the score scatterplot corre-
sponds to a single condition: a patient and timepoint. Rather than being identified
by a whole distribution of phenotypes, it is now identified by only two points.
Plotting the scores and loadings together produces a visual interface greater
than the sum of its parts. The score scatterplot shows a visual representation of
the data in two dimensions. The simultaneous overlay of the loadings on top of
the scores comes with an additional benefit. Because the x and y coordinates of the
biplot refer to the same principal components, the coordinates of a loading and
a score are related. If pc  is displayed along the x axis, a phenotype with a high
loading in pc  will have a large x coordinate, and any condition with high levels of
that phenotype will also have a large x coordinate. In this way, the geometric dis-
tance between a phenotype’s loading point and an experimental condition’s score
point is a proxy for how highly expressed that phenotype is under those condi-
tions. Finally, combining color and size to identify a scatterplot point with both
its patient and relative sample time allows complete visual identification of all
relevant information about the samples.
The largest trend revealed by the biplot is the difference between the pheno-
type distribution upon infusion and all other timepoints. This is represented by
the entire first and fourth quadrants containing scatterplot points from “day ”
measurement only. The distinction between day  and the other timepoints is de-
scribed almost exclusively by the first principal component, which explains the
largest fraction of the total variation in the data. Thus, it is the largest trend in the
data, larger than any other correlation between any of the variables. The loading

rays that point most strongly in the +x direction, such as cd27+ cd28+ cd62l−,
describe the phenotypes that most readily distinguish themselves by their appear-
ance on day .
The second most significant trend is the patient-by-patient clustering of the
data, clearly revealed through the projection onto the first two principal compo-
nents. In this projection, not all patients cluster closely together, e.g. f- and
f-. But many of the other patients, e.g. f-, f-, and f-, clearly localize in
their own area of principal component space. This means that, on a coarse level,
after the phenotypes have transformed from their original distribution, measured
upon infusion, they tend to converge to a patient-specific distribution that does
not change much with time. Some of distributions are clearly associated with a
particular phenotype, such as the high expression of cd27− cd28− cd62l− in f-.
The patient by patient clustering shows that cross-patient variability is a continu-
ing challenge to adoptive T cell therapies. Because individuals’ immune systems
vary so starkly, due to a host of genetic and environmental factors, it is difficult to
know the specifics of what effects a particular T cell clone will have. With more
patient data, these differences could be quantified and understood.
Time-based regression
In addition to understanding what the biggest sources of variation and correlation
in the data are, it is also useful to identify which phenotypes grow and which ones
decay. A pls model that predicts the time from the phenotype distribution, based
on the work of Rivet et al. [], automatically separates out the strongest grow-
ing and decaying phenotypes with only a single tunable parameter. This model
reaches its highest performance with only a single principal component. Pheno-
types with positive loadings in this pc correspond to growing phenotypes, and
negative loadings correspond to decaying phenotypes. Plots of these two groups

are shown in Figure -.
The two groups exhibit clear growth and decay phenomena. It is interesting
that such a simple model can capture much of the essential dynamics. Phenotypes
were assigned one of the two groups selected if their magnitudes were greater than
50% of the maximum expression that day.
Despite the cross-patient variability, our ability to construct an accurate re-
gression model of the time from the phenotype data suggests that there are con-
sistent time-based phenomena occurring in the patient’s response to adoptive T
cell transfer. The time-based structure helps us understand in detail which phe-
notypes emerge later after transfer. By studying the late-emergent phenotypes in
greater detail, we will seek to identify the underlying biological reasons for their
emergence.
. Discussion
In this thesis chapter, we have shown the power of correlation analysis, pca, and
pls for analyzing newly available multidimensional facs data. We have also shown
how biplots can identify a wealth of global information about a dataset, and de-
veloped a visualization technique—the subway plot—for comparing specific time
trajectories of phenotype distributions, while identifying the most relevant surface
markers whose variation determines the phenotypes’ fluctuations. These are the
surface markers to which further experimental effort should be devoted.
Our analysis methods are powerful techniques that should be incorporated into
the workflow of newer, more complicated data collection schemes. Nevertheless,
these techniques are still subject to limitations. First, the linear aspect of the mod-
eling may prove too simplistic for certain relationships, such as oscillatory varia-
tion. This can be mitigated to a certain extent through inverse transformation, if

the form of the data is known. For example, an exponential relationship can be
linearized by taking the logarithm of the exponentially growing quantity. Further-
more, the simplicity of the pls model does not take into account systematic noise
in the phenotype expression levels that is uncorrelated with the age of the cells.
Filtering this data out via methods such as o-pls and its extensions [,,,]
would be a useful next step.
Finally, experiments to test the insights revealed by the analyses are essential.
Our analyses have provided a system for identifying where experiments should
be directed, but they cannot bring additional biological meaning to the problem.
For example, if our pls model identifies cd27− cd28− cd62l− is identified as a
particularly phenotype in determining T cell age, we must understand why this
is so. What other surface markers are present on cd27− cd28− cd62l− cells? Are
these markers also good indicators of late time? How do cd27− cd28− cd62l−
cells function? Which immunogenic properties do cd27− cd28− cd62l− cells ex-
hibit? Experimental work is currently being done in this direction, but has not
yet produced results. With the upcoming experimental data, our analysis work
has tremendous potential for expansion, and we hope the techniques developed
in this thesis chapter will be used later on to guide experiments that reveal the
behavior and theraputic abilities of adoptively transfered T cells.
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Figure -: Measurement condition correlations highlight the primary impact of
time on phenotype distribution. Labels for each column correspond to the row la-
bels, moving from left to right. Each dash-separated section of the labels describes
a particular experimental condition. The first section describes the day,  – . The
second section describes the cytokine regimen, and the third section describes the
activation protocol: “o” for okt antibody, and “m” for andibody-coated beads.
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Figure -: Subway plots for the first facs experiment, performed on cd T cells
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Figure -: Subway plots for the second facs experiment, performed on cd T cells
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Figure -: Subway plots for the third facs experiment, performed on cd T cells
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Figure -: Subway plots for the first facs experiment, performed on cd T cells
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Figure -: Subway plots for the second facs experiment, performed on cd T cells
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Figure -: Subway plots for the third facs experiment, performed on cd T cells

cd4+ cells
cd8+ cells
Figure -: Measurement condition correlations highlight the large cross-patient
variability of the cd4+ cells and the inconsistency of data from patient f-.
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Figure -: Comparing cd8+ phenotypes via their variance and the magnitude of
their loading in the first principal component of a covariance pca leads to a clear
separation of a small subset of highly variable phenotypes.
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Figure -: A biplot of the data projected onto the first two principal components
along with the loadings of each variable for those components identifies the sep-
aration of early-time point and late-time point data and the clustering of data by
patient. Circle colors represent patient ids, while circle sizes qualitatively repre-
sent the sample day. Phenotypes are identified with a two-part abbreviation. The
letter indicates the facs experiment (and thereby the choice of surface markers),
and the pluses and minuses indicate the expression levels of the surface markers
that define a particular phenotype. For example, cd27− cd28− cd62l− is identified
as C−−−.
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Figure -: A time-based pls model identifies and separates rapidly growing phe-
notypes into growing and decaying.
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Chapter
Differences between blood and spleen
cytokine expression levels revealed
by a latent-variable regression model
. Summary
The majority of essential immune processes, including antigen presentation, se-
lection, and rest, occur in the tissues. But measurements of the response in the
tissues are often prohibitive. Blood measurements, particularly cytokine levels,
often serve as a proxy measurement for tissue immune response because they are
easy to perform and descriptive. Despite their frequent use as indicators, is un-
clear how cytokines in the blood relate to the crucial immune activity that occurs
in central immune organs. We decided to establish how closely serum and tissue
cytokines correlated, using highly multiplexed xMap data from collaborators at
Stanford University. The xMap data described levels of  cytokines in the serum
and the spleen of mice at rest and infected by two strains of L. monocytogenes. To
be able to understand the highly multidimensional data, we calculated correla-
tions in cytokine levels between serum and spleen cells. The correlations were

surprisingly diverse, so we modeled them with a multidimensional latent-variable
regression (o-pls). This thesis chapter describes the data collected, outlines in de-
tail the model used to analyze the data, and highlights the following system-level
biological insights obtained from the data:
. the correlations between serum and spleen cytokines are not simply one-to-
one
. using only the correlations between serum and spleen, o-pls latent-variable
regression models organize the infected cytokine distributions into h. and
h. time groups
. the key cytokines in each time group are distinct and differ between serum
and spleen
. the models also find a common cytokine profile associated with different
strains of L. monocytogenes infection
By analyzing the correlations between serum and spleen cytokine levels, we con-
structed a model that extracted biologically relevant information. The highly dis-
tinct cytokine profiles expressed by the serum and the spleen suggest that a deeper
understanding of the relationship between tissue and serum cytokine levels is nec-
essary for serum measurements to serve as an accurate proxy for the immune tissue
response.
. Introduction
One of the main functions of the immune system is to fight pathogens in barrier
tissues (e.g., skin, lungs, and gut) and in blood. However, the majority of immune
cells are found in central organs such as spleen, lymph nodes and follicles, where

they present antigen, become activated, proliferate and finally rest in wait of an-
other activation signal. In clinical settings, it is easiest to perform immune mea-
surements in blood because it is readily accessible with minimally invasive proce-
dures. Of the many immune molecules that can be measured in blood, cytokines
are especially informative direct indicators of immune function. Although blood
cytokine measurements are often used as a proxy for tissue cytokine levels, no one
has established in depth how the cytokine levels actually relate to one another.
Athanassakis and coworkers have suggested that serum cytokine levels correlate
directly with spleen cytokine levels [], but this correlation did not extend to all
measured cytokines and was not statistically supported. Nakane and coworkers
measured cytokine levels in the serum, spleen, and livers of mice with listerio-
sis and found substantial differences in the behavior of some cytokines, but their
measurements focused only on only three cytokines, and their time-resolution was
on the level of days []. Because the correlation between spleen and tissue cy-
tokine levels underpins immunologists’ understanding and clinical measurement
of many immune processes, it must be studied in greater detail.
Through the emergence of antibody-coated bead (xMap) techniques [], im-
munologists can now measure many more cytokines simultaneously. xMap beads
are internally-dyed polystyrene spheres. Their internal dye mixture allows indi-
vidual beads to be uniquely identified, and their surface chemistry allows specific
binding to a desired analyte. By combining these two independent parameters,
xMap instruments detect up to  cytokines simultaneously in a single sample
with flow cytometry. xMap techniques thus offer the prospect of a deeper under-
standing of the relationship between spleen and serum immune responses through
direct comparison of multiple cytokines from both regions.
Goldberger and coworkers [] recently collected a novel xMap dataset uniquely
capable of addressing the question of spleen-serum correlation (Figure -). They

measured  cytokines in the blood and spleen of mice subject to two strains of
Listeria monocytogenes infection and an uninfected control. Analyzing the corre-
lations in the dataset reveals that the relationship of cytokine levels in the serum
and spleen is complicated (Figure -). In comparing serum and spleen cytokine
measurements for the same cytokine we might expect one of three outcomes:
. spleen and serum levels could be positively correlated for the same time
point, suggesting both are destinations from a common source.
. spleen and serum levels could be negatively correlated, suggesting a source
where the cytokine travels from one to the other
. time lapse variations of . or ., suggesting that these events happen in a
time delay.
Although some of the above-mentioned correlations do exist in the data, the most
common relationship displayed is correlation between different cytokines in the
serum and spleen. This complexity immediately invalidates the naı¨ve picture of
one-to-one correlation between serum and spleen.
The biological picture painted by xMap data in Figure - presents two distinct
analysis challenges: understanding the complex relationship between the cytokine
sets, and dealing with the noisy, high-dimensional data. These challenges require
that we use multivariate statistical techniques to discern the most informative cy-
tokines and create robust models that make sense of the data. Latent variable
models are a simple and powerful type of statistical technique used successfully
for many decades in other fields to explore datasets with at least as many dimen-
sions as the cytokine data. [, , , , ]. They have recently been applied
to problems in biology as well [,,,,,]. The fundamental principle
common to all such models is to reduce the dimension of a set of data by defining
a few new (latent) variables that are weighted sums of the original (manifest) vari-

ables. Calculating latent variables that effectively describe the multivariate data
creates a model that is at once more robust and general than naı¨ve multivariate
linear regression. Furthermore, the latent variables can serve as useful indicators
of important phenomena in the data. Examining the data in the sub-space defined
by the latent variables can reveal patterns in the observations, such as a reveal-
ing separation or clustering of the data points. Examining the weights that define
the latent variables reveals closely associated, correlated groupings of the manifest
variables. Often, latent variable models will also relate two blocks of data with a
regression. Reducing the data to latent variables makes the regression both robust
and general. Latent variable regression thus holds promise for both the noise and
complexity challenges posed by the data.
In order to elucidate the relationship between spleen and serum cytokine lev-
els, we constructed a latent-variable model of the data collected by Goldberger and
coworkers []. Our model reduced the multidimensional data onto a subspace
that exposed biologically relevant phenomena. The subspace identified that, in all
cases but the uninfected spleen, time was the most important discriminator of cy-
tokine response. Each time point had its own signature cytokine profile, and the
cytokines differed starkly between serum and spleen. The latent variables that de-
fined the projection identified the clusters of cytokines associated with each time
point. The cytokines grouped by the latent variables were all biologically relevant,
even if they did not always belong to a single, easily-identifiable grouping. Many
of the cytokines were consistent across different infection strains, identifying a
common cytokine profile associated with L. monocytogenes infection. The common
profile and time separation were not observed in the spleen of the control mice,
supporting a role for infection in creating these distinct cytokine profiles.
Our results first establish the complexity of the relationship between serum
and spleen cytokine levels and then unravel the complexity by describing the

global features of that relationship. In doing so, they also establish latent variable
regression as a useful method for analyzing high-dimensional immune-phenotyping
data. The striking differences between serum and spleen cytokine measurements
identified by our models establish that serum cytokine levels are poor direct in-
dicators of immune processes in the tissues. Instead, the complex relationship
between these two sets of cytokines must be explored with detailed experiments,
and predictive models must be established to find a more accurate interpretation
of serum cytokine levels.
. Statistical Model
.. o-pls effectively models the cytokine data
As latent variable models are an entire class of analysis technique, we chose a
particular member of that class: o-pls, a regression technique particularly well-
suited for the analysis of the spleen-serum cytokine correlation data [, ].
o-pls builds a regression that maps two blocks of data to one another—here, the
serum and spleen cytokine levels, respectively. The unique feature of o-pls is
its fundamental separation of variation that is predictive between the two blocks
and variation that is orthogonal to the correlations between them. Predictive vari-
ation constitutes the core of the model: it helps explain each block in terms of the
other. Orthogonal variation is the compliment of predictive variation: it encom-
passes any variation that is unique to the individual blocks and is not related to
the mapping between them. For modeling biological systems, the presence of the
orthogonal group is essential. It allows the model to account for the systematic
noise often present in biological data []. Explicitly accounting for the system-
atic noise leads to more interpretable models and allows a deeper understanding
of the sources of noise in the data, such as impurities in the compounds or base-

line fluctuations inherent to the measurement []. The mathematics of o-pls
are explained in detail in Section ..
Given training data in two blocks X and Y of equal importance, o-pls con-
structs a model that contains five parts:
. a low-dimensional latent-variable predictive model of the parts of X that cor-
relate with Y
. a low-dimensional latent-variable predictive model of the parts of Y that cor-
relate with X
. a low-dimensional latent-variable orthogonal model of the systematic noise
in X, which is completely uncorrelated with Y
. a low-dimensional latent-variable orthogonal model of the systematic noise
in Y , which is completely uncorrelated with X
. a linear regression that removes the uncorrelated parts of X and Y , then sym-
metrically maps them onto one another.
Each of the low-dimensional models consists of a set of a few latent variables,
called components. Each component is a weighted sum of the manifest variables.
The weights of this sum are called loadings, and they are constrained so that the
sum of their squares is one. The data points, as expressed in the reduced dimen-
sions of the latent variables, are known as scores. The components are defined so
that they are completely independent of one another, yet capture as much of the
variation and correlation in the data as possible. The first component captures the
most variation, and it decreases from there. Although there could be as many com-
ponents as there are variables, only a small handful are used in practice. In this
way, the components provide an effective summary of the most relevant sources
of variation in the data. By exploring the regression and studying the scores and

loadings of both the predictive and orthogonal components, o-pls gives a thor-
ough description of the correlation and noise in the data.
o-pls’s explicit separation of predictive and orthogonal correlations provides
an effective filter for dealing with noisy biological data, but it also gives the method
three distinct advantages over more basic latent variable models such as Principal
Component Regression (pcr) [, ] and Partial Least Squares Projection onto
Latent Structures (pls, also known as Partial Least Squares Regression) [,].
The first advantage of o-pls models is the symmetry between the X and Y data
blocks that they impose. Most other latent variable models require distinguishing
between a set of independent (X) and dependent (Y ) variables. Any regression
in these models attempts to establish a one-way relationship from X to Y . With
the serum and cytokine data, however, one could argue compellingly for either
dataset to serve as the independent set: when injecting recombinant cytokines into
blood, changes in cytokines can be measured in splenocytes [,], and when
introducing cytokines to splenocytes (e.g. through genetic manipulation such as
viruses encoding cytokine genes or conditionally expressed cytokines in transgenic
mice), one can measure changes in serum cytokines []. It is therefore useful
not to make any artificial distinction about dependence and instead to treat both
sets of data as symmetric blocks that are equally dependent on one another. The
symmetric relationship that o-pls establishes between X and Y makes it the most
logically appropriate choice to model this data.
The second advantage is the improved relevance of the latent variables. By
explicitly identifying and filtering out the uncorrelated parts of the data, o-pls
produces a filtered dataset that decomposes into relevant latent variables that are
easier to interpret directly. Without the filtration step, latent variables would in-
corporate the orthogonal variation into their loadings, making it much more diffi-
cult to understand what observations are being distinguished and which manifest

variables are truly relevant. The references that establish o-pls [,,] pro-
vide a detailed mathematical treatment and examples of this relevance.
The final advantage of o-pls follows from the high relevance of the latent
variables it produces. In almost all latent variable regression models, particularly
pls, the latent variables obtained are extremely sensitive to the choice of manifest
variables used in the data. Even a small percentage of manifest variables that are
uncorrelated between X and Y can result in a model whose latent variables are
meaningless and impossible to interpret. The need to provide interpretable la-
tent variables imposes an additional problem on such models: variable selection.
There are a variety of variable selection techniques, and all require parameteri-
zation, either by a cutoff in the correlation value, or a stochastic optimization al-
gorithm, to optimize a measure of model quality across an unfamiliar and rough
space [,–]. The sampling algorithms can take a long time to converge, due
to the unpredictable nature of the quality statistic, and the exponentially large
number of variable combinations precludes any verifiably global optimum solu-
tion. In o-pls, however, while variable selection can still be performed, it is often
unnecessary, as the structured noise contained in the uncorrelated manifest vari-
ables is explicitly captured—and analyzed—by the orthogonal part of the model.
The orthogonal filtration makes the predictive part of the model more robust to
noise and uncorrelated variables, eliminating the need for costly and complicated
variable selection.
By removing the necessity of variable selection, o-pls serves as a parameter-
free technique for understanding the data. The only three parameters in the model
are the number of predictive (a), Y-orthogonal (aYo), and X-orthogonal (aXo) com-
ponents to keep. These parameters, however, are determined explicitly by using
cross-validation to calculate the predictive error and finding the optimal numbers
of components that minimize this error. In this way, o-pls can generate com-

Infection a aYo aXo Q
2
X Q
2
Y rXˆ rYˆ
none 3 1 2 0.96 0.96 0.81 0.81
L. monocytogenes 5 1 2 0.92 0.96 0.89 0.95
L. m.-L.p.FlaA 3 1 2 0.97 0.96 0.93 0.87
Table .: Cross-validation and goodness of fit statistics show the high quality of
the o-pls models. The a columns show the number of components in each model.
a is the number of predictive components, aYo is the number of Y -orthogonal com-
ponents removed from X, and aXo is the number of X-orthogonal components
removed from Y . Q2 ∈ (−∞,1] expresses the quality of the model upon cross-
validation similarly to how the familiar R2 expresses the percentage of variance
in the original data explained by the model. r =
√
R2, the Pearson correlation co-
efficient, is tabulated in the right-most columns for both predictive models. All
statistics were calculated from their original definitions for o-pls by Trygg and
Wold [].
pletely parameterized models from the data with no arbitrary setting or cutoff
parameter.
To model the data from our collaborators [], we made three separate o-pls
models: control, wild-type, and mutant—one per infection strain. To determine
the dimensionality of the models, we performed the deterministic minimization
technique described above on all three models. The resulting validated models all
had a low dimension (Table .), highlighting the success of o-pls in projecting
the -dimensional data onto low-dimensional subspaces.
Because of the thorough cross-validation, our o-plsmodels are both parameter-
free and high-quality. The models’ quality is visible by analyzing statistics, such as
R2 and Q2, that describe the cross-validation and the prediction (Table .). Only
the uninfected model, which has the least potential for meaningful relationships
between cytokine levels, has a Pearson correlation coefficient below 0.85, and all
models cross-validate well, exhibiting Q2 values near the maximum of 1, when
values above 0.5 are usually considered good [].

.. Biplots simultaneously visualize multiple relationships be-
tween variables, observations, and latent variables
The key advantage of the o-pls models is their ability to turn the unmanageable
swath of raw data (Figure -) into a more manageable form. By examining the
components of the o-pls models, the loadings that define them, and the way the
cytokine data are projected onto them, we can turn the original data into mean-
ingful conclusions.
A common visual examination technique for latent variable models is the bi-
plot []. Biplots visualize two- or three-dimensional latent-variable representa-
tions of a dataset. In o-pls, they are used to analyze both predictive and orthogo-
nal models. Each axis of a biplot corresponds to a single latent variable. The biplot
displays the relevant information about the latent variables by superimposing two
scatterplots, hence its name. The first scatterplot shows the scores—the projection
of the data in the subspace defined by the latent variables. Every score corresponds
to an observation, and the observations are often identified with relevant informa-
tion. On top of the score scatterplot sits the loading scatterplot. This plot shows
the loadings that define each component. Every point on the loading plot corre-
sponds to a manifest variable, rather than an observation. Loading points are often
drawn with lines to the origin for clarity. The scatterplots may seem unrelated, but
they share the same dimensions, so the visual proximity they create corresponds
to an underlying sense of similarity or relationship.
It is best to ground the abstract description of biplots with a specific example
(Figure -). In this contrived dataset, we seek to compare X data of three cy-
tokines (il-1, il-2, and il-3) to Y data of two other cytokines (tnf-α, mip-1α). The
data were designed to exhibit noise, variation in X that is correlated with Y , and
variation in X that is uncorrelated with Y . The complete data are plotted in Fig-
ure -a, an ideal example of the difficulty of visualizing multidimensional data.

The X data are represented with the three spatial dimensions. The spatial data
are composed of two oblate spheroids (a large, tall, skinny cluster and a small,
flat, wide cluster) whose major axes point in the same direction, but whose second
axes are orthogonal. The Y data are represented with color, with blue representing
tnf-α, and pink representing mip-1α. Purple shades represent a mixture of the
two. There is a gradient from pink to purple along the second axes of the smaller
spheroid and a gradient from blue to pink along the major axes. Although the data
are difficult to visualize, the major axes of the ellipsoids are clearly the largest di-
rection of variance, and they are correlated directly with mip-1α. The second (flat)
axis of the small ellipsoid is coordinated directly to tnf-α, and therefore it makes
up the second most useful dimension. Finally, the third axes of both ellipsoids is
completely orthogonal to Y . o-pls effortlessly detects all three of these features.
o-pls allows us to project the data onto a lower-dimensional subspace. Two
such possible subspaces are identified in Figure -b. The green plane consists of
the first two predictive components. It cuts through the X data along the direc-
tions that are directly related to Y . The yellow plane shows that the orthogonal
part of o-pls finds the uncorrelated direction in X as well. We can analyze both
of these projections with biplots, shown in Figure -c – d. The scores of the pre-
dictive biplot in Figure -c show the clustering pattern of the two ellipsoids much
more clearly than the three-dimensional plot, a “top-down” view. They also out-
line both directions of variation in Y , since the predictive components correlate
strongly with Y . The loadings on this biplot show the orientation of the top-down
projection in terms of the originalX variables il-1 – il-3. Because the scores cluster
heavily toward il-3, we can see that, of the manifest variables, it is the one with the
greatest variation. Because il-3 is plotted exactly along the X axis, the further left
a point is along the X axis, the higher its il-3 value will be. The orthogonal biplot
in Figure -d has a similar role. Instead of the top-down perspective, however,

the biplot shows a side view. In the side view, the pattern in Y from mip-1α (pre-
dictive component ) can still be seen, but the second part of the pattern is gone,
because the ordinate is now plotting systematic noise: points along the y axis of
the figure vary with no particular order. By orienting this plot by the loadings, we
can see that this perspective shows that the axis connecting the clusters at a  de-
gree angle in the il-1 – il-3 space. It is also consistent with the small flat sphere’s
higher il-3 levels, even though the flat sphere is no longer immediately on top of
the il-3 loading. The noise perspective shows that this part of the data is enriched
in il-1 and il-2 as well. In short, while viewing this multidimensional dataset in
full tells us little about its essential features, finding its principal dimensions with
o-pls reveals useful information about the shape and nature of the data.
. Results
Our model analyzed xMap data obtained by our experimental collaborators. Gold-
berger and coworkers [] performed Luminex xMap measurements of cytokines
in mice following infection with Listeria monocytogenes. Mice were divided into
three groups: one uninfected control, one infected with wild-type L. monocyto-
genes, and one infected with L. monocytogenes-L.p.FlaA—a L. monocytogenes strain
designed to activate the Nlrc inflammasome []. Spleen and sera were collected
at four and twelve hours post-infection. Samples were taken from four mice per
group, and two technical repeats were done in the Luminex experiment.
.. One-to-one correlation between serum and spleen fails to
explain the xMap measurements
Visual inspection of the spleen cytokine levels plotted against the serum cytokine
levels largely invalidates the unbiased assumption of one-to-one correlation be-

tween the spleen and the serum for every cytokine (Figure -). The visual conclu-
sion is supported quantitatively. If spleen and serum cytokines had a one-to-one
relationship, we would expect to see self-correlations (diagonal entries in the plot
matrices in Figure -) close to unity. In reality, the average self-correlations (di-
agonal entries in the plot matrices) [] are 0.15, −0.035, and −0.13, for the no-
infection wild-type, and L. m.-L.p.FlaA infections, respectively (Figure -). Such
low correlations are striking. While they do imply a small tendency toward posi-
tive correlation during the normal resting state, this correlation is too weak to sup-
port. The slight anti-correlations contradict the one-to-one correlation assumption
even more strongly.
The scatterplots in Figure - also refute the assumption of independent cy-
tokine levels. If serum and spleen cytokines were independent of one another, we
would expect the off-diagonal correlations in Figure - to be vanishingly small.
In reality, across all infection conditions, at least 92% of the off-diagonal elements
with finite correlations have values outside of the 95% confidence interval of this
assumption: a vast majority of the off-diagonal elements signify some measure
of correlation between a cytokine in the serum and other cytokines in the spleen.
The existence of the off-diagonal correlations is consistent with previous results,
since since it is known that many cytokines are regulated by other cytokines: in-
deed, in a systematic immune response, it would be surprising if off-diagonal cor-
relations were absent []. Nevertheless, the pervasiveness of the correlations,
even among a general set of cytokines without an underlying biological selection
criteria, speaks to the complexity of the relationship between spleen and serum
cytokine levels. Clearly, the simplifying assumptions of independent, one-to-one
relationships between serum and spleen cytokines are invalid. Any model based
on them is insufficient to describe the relationship. We must instead turn to a
multivariate model that embraces the entire correlation structure: o-pls.

.. Biplots reveal a clustering of the data into h. and h.
time points
To understand both the sources of correlated variation in the data and the sources
of structured noise, we made biplots of predictive components against orthogonal
ones (Figure -). The first predictive component in all three models has posi-
tive loadings for all variables. By definition, it reflects the average net correla-
tion between the X and Y data []. Because it does not group or distinguish any
variables, it is of no great interest to us; for us, the second predictive component
becomes the most important. The biplots in Figure - therefore span the second
predictive component and the first orthogonal component.
A pattern emerges from examining these biplots: in the sera and spleens of
infected mice, the second principal component clearly separates the data into
time-based groups of h. and h. on opposite sides of the origin. As an inter-
nal control, we note that uninfected mice do not display this time separation in
the spleen, because without infection, immune tissue cytokine levels are in steady
state with only small perturbations (Figure -). This separation is particularly
vauable, because the model does not initially know anything about time: the sep-
aration into timepoints was derived entirely from the covariation of spleen and
serum cytokines.
Examining the loadings of the second predictive component (along the ab-
scissa) explains which cytokines are responsible for the time point separation and
shows the associations between cytokines and time points (Figure -). In unin-
fected mice, spleens show no separation between time points, and sera show mud-
dled differences that probably represent steady state changes in cytokines over
time. However, after infection with L. monocytogenes, we see a clear separation be-
tween time points with all the mice in each group driving the differences to varies
degrees.

In the uninfected serum, the separation between the time points is mediated
by mip-1α levels at h. and tnf-α levels at h. (Figure -a). In the serum dur-
ing wild-type L. monocytogenes infection (Figure -b), tnf-α is instead associated
strongly with h., and il-5 is the strongest marker of h. In the L. monocytogenes-
infected spleen, however, tnf-α and mip-1α are both associated strongly with h.,
while rantes, tgf-β, and il-2 are all strongly associated with h. Finally, for the
L. m.-L.p.FlaA mutant infection (Figure -c), a related set of cytokines emerge. In
the serum, tnf-α is strongly associated with h., while il-5 and tgf-β are asso-
ciated with h. In the spleen, just like in the wild-type L. monocytogenes infec-
tion, the h. data is strongly associated with rantes, tgf-β, and il-2, while the
h. observations are associated with ifn-γ, while mip-1α plays a secondary role.
These results are summarized in Table ., which demonstrates how the correlated
groupings of cytokines that o-pls detects describe the infections.
The other striking feature of this time-based grouping of cytokines is how
starkly different the corresponding cytokines are between serum and spleen. At
a given time point, there are no common cytokines between the two datasets. The
dissimilarity of the spleen and serum cytokine sets is a strong indicator that blood
serum measurements do not provide an accurate picture of the current immune re-
sponse in the tissues. Working out how the cytokine levels in one relate to the other
will require additional modeling and measurements. Determining the factors that
influence the relationship is a rich biological question requiring a significant effort.
The time separation painted by the biplots is clear, but the association between
loading and score is only an implication: there could potentially be hidden vari-
ables in the model that cause a score to map closely to a loading. To determine
whether or not the associations between time point and cytokine level implied
by the biplots are reflected in the cytokine levels themselves, we grouped the cy-
tokine levels by time point (Figure -). This regrouping would not have been

Infection Serum Spleen
h. h. h. h.
none mip-1α tnf-α – –
L. monocytogenes tnf-α ↓ il-5 il-2 tnf-α ↑
il-12p7 tgf-β mip-1α
rantes il-1β
ifn-γ
L. m.-L.p.FlaA tnf-α il-5 il-2 ifn-γ ↑
ifn-γ ↓ tgf-β ↑ tgf-β ↓ mip-1α
il-12p7 rantes kc
ip-1
Table .: Cytokines with large-magnitude loadings in the predictive component
define a common profile of L. monocytogenes infection (highlighted in red). Listing
the most relevant cytokines together also shows the distinction between serum and
spleen, infected and uninfected cytokine fluctuation and allows the identification
of temporal patterns in cytokines that appear first in the serum and then in the
spleen, or vice versa. The patterns are identified with arrows, which point down
to indicate the “source” and up to indicate the “destination.”
obvious without the insight provided by the biplots, but it serves as an effective
verification of that insight, as the regrouped data exhibit the same separations as
in the biplots. In particular, the regrouped plots in Figure -a explain why there
is no time-separation in the uninfected spleen biplot: hardly any of the cytokines
change with time, so there is no variation to detect. In some cases, such as the
infected spleen (Figure -b – c), the h. cytokines and h. cytokines are not in-
versely related, as one might assume from their separation onto opposing groups.
Instead, the distinction between these groups is one of growth: cytokines associ-
ated with h. timepoints have moderate to high levels that do not grow at h.,
while the h. cytokines grow noticeably from their low h. levels. Nevertheless,
there is always a clear visual difference between the behavior of both groups, so
the highlight plots successfully show that the intuition developed in the biplots is
accurate.

.. o-pls clustering reveals the strongest relationships between
cytokines in the serum and spleen
In addition to highlighting the stark differences between serum and spleen cy-
tokine levels, the separation of the data into h. and h. timepoints also identi-
fies some of the most significant relationships between serum and spleen cytokine
levels. By using the timepoint as a bridge, we can determine relationships between
the spleen and serum cytokines during infection. Sometimes, these relationships
are not directly played out in a : correlation, such as the rather weak relationship
between serum tnf-α and spleen il-2, despite both of them being associated with
h. time points (Figure -b). Other times, however, they are quite strong, such as
the correlation between serum il-5 and spleen ifn-γ, il-1β, and mip-1α (Figure -
b – c). Regardless of the strength of the underlying correlation, the spleen-serum
associations created by the biplots have meaning because the association based on
timepoint is inherently meaningful.
As in the correlations, none of the relationships is a simple one-to-one autocor-
relation. This speaks to to the strong differences between the cytokines and the
difficulty of extrapolating to tissue immune responses from serum measurements.
However, one starting point for identifying a mapping between the two sets of cy-
tokines is a temporal pattern identified by the model. In this pattern, a cytokine is
strongly expressed in the serum at one time point, and in the spleen at the other.
Each infection variant exhibits at least one such relationship (Table .). In the
wild-type L. monocytogenes infection, tnf-α is in the serum at h., and the spleen
at h., and in the L. m.-L.p.FlaA infection, tgf-β from is in the spleen at h. and
in the serum at h., and ifn-γ is in the serum at h. and in the spleen at h..
The temporal may not correspond to biological transport, but they do elucidate
one of the many complex mechanisms occurring during infection.

.. o-plsmodels reveal a common cytokine profile of L.mono-
cytogenes infection
Cytokine levels in the uninfected spleen seem almost constant over the timescales
measured (Figure -). Yet even without infection, cytokines in the serum fluctu-
ate over these timescales. Thus, the presence of cytokine fluctuation alone cannot
serve as an indicator of infection. The picture in sera is more complex, because
blood is a conduit of cells, proteins, and bacteria. It is a complex representation
of events coming from not only the spleen, but also all other organs. However,
stepping back from the specifics of the biplots and analyzing them together re-
veals important general information about cytokine responses in L. monocytogenes
infection.
Examination of the biplots and the significant cytokines in them (Table .)
shows that rather than the presence of variation in cytokine levels, infection is in-
dicated by a cytokine profile common to both infections. The common profile is
defined by tnf-α in the serum at h., il-5 in the serum at h., il-2, tgf-β, and
rantes in the spleen at h., and mip-1α and ifn-γ in the spleen at h. (high-
lighted in red in Table .). These cytokines account for most of the highly-loaded
cytokines in the second predictive component of the infected models. The pres-
ence of such a core indicates that L. monocytogenes infection, even by a mutant
strain, induces a well-defined immune response over short time scales. It also
testifies to the power of o-pls and biplot techniques for detecting this common
structure automatically.
The common core of infection also starkly separates infection from the unin-
fected state. Even if we ignore the idleness of the uninfected spleen, we see that
uninfected cytokines vary in different ways from infected cytokines. In the unin-
fected serum, h. timepoints are associated with mip-1α and h. timepoints are
associated with tnf-α. During infection, however, tnf-α is associated with h.,

while mip-1α is associated with h., and in the spleen at that, not in the serum.
tnf-α and mip-1α are shown to play a role in both infected and uninfected mice,
but their behavior changes. The difference shows how L. monocytogenes infection
rewires already active signals in addition to introducing new, independent ones.
.. o-pls models reveal strain-specific infection response
Despite sharing a large common core of cytokine activity, the immune responses
to the different L. monocytogenes strains do express unique features. The mu-
tant L. m.-L.p.FlaA infection engages additional serum cytokines: ifn-γ at h. and
tgf-β at h. The wild-type L. monocytogenes infection, for its part, engages tnf-α
at h. in the spleen: a feature absent in the L. m.-L.p.FlaA infection.
.. The orthogonal component in the biplots identifies inter-
mouse variation in serum and spleen
In addition to displaying useful information about correlated variation that groups
cytokines and observations into relevant clusters, the biplots also inform us about
the “structured noise” [] in the model—variation across mouse or sample that
may not have systematic biological meaning but cannot be controlled for. This
is intra-block variation local to either the serum or the spleen and unrelated to
the correlations between them. The structured noise is plotted along the ordi-
nate in the biplots. In every biplot (Figure -), this axis separates mice from one
another, which is completely consistent with its definition: variation that distin-
guishes mice from one another is noise, uncorrelated between serum and spleen,
as all mice were subject to the same treatment.
In the serum, the orthogonal component separation usually distinguishes a par-
ticular mouse or two at h and shows the cytokines that set that mouse apart. In

the spleen, the orthogonal component typically separates a mouse at h.. For
example, in the L. m.-L.p.FlaA infection (Figure -c), the serum orthogonal com-
ponent draws a contrast between Mouse , which has relatively higher levels of
tnf-α and il-12p7, and Mouse , which has higher levels of mcp-1. Similarly,
the spleen orthogonal component in the wild-type L. monocytogenes infected-mice
(Figure -b) separates Mouse , which has elevated levels of the cxc cytokines kc
and ip-1, and Mouse , which has elevated tnf-α. The continued appearance of
tnf-α in both the predictive and orthogonal components highlights a subtle inde-
pendence in their interrelationship: although the two classes of components are
mathematically constrained to be opposites of one another, cytokines can score
highly in both of them, in the same sense that a normal distribution can have both
a high mean and a high standard deviation without one affecting the other.
The orthogonal, inter-mouse variation also serves to distinguish the L. mono-
cytogenes strain infections from one another. In the h. spleen, these differences
involve the interplay between predictive variation and structured noise for the cy-
tokines il-1β, ip-1, and kc. In the wild-type L. monocytogenes infection, il-1β
plays a prominent role in the predictive association between serum and spleen
and is a reliable marker of the h. timepoint. ip-1 and kc, on the other hand,
have only a small correlated contribution and instead have sizable orthogonal
loadings that indicate they are a key source of mouse-to-mouse variation. In the
L. m.-L.p.FlaA infection, this dichotomy is changed. il-1β instead makes hardly
any predictive contribution, and is instead strongly associated with the orthogo-
nal, structured noise in the spleen. ip-1, on the other hand, is now solidly predic-
tive, and has hardly any orthogonal loading at all. kc-has also become predictive,
but still maintains a strong orthogonal contribution, and mip-1α, while always be-
ing a core predictive cytokine, now also has a significant orthogonal contribution
as well. It is likely that some of this interplay between predictive and orthogo-

nal variation is due to the relatively small number of mice included in the cohort.
If the number of mice were greater, a more consistent picture of structured noise
could emerge. Nevertheless, the current o-pls models succinctly identify the gen-
eral core features of L. monocytogenes infection but are still capable of capturing
differences between variants.
Exploring and analyzing the inter-mouse variation is a sizable advantage for
o-pls over methodologies such as pls with variable selection: variables that have
both a high predictive contribution and a high orthogonal contribution can be left
in the model to provide useful information rather than being discarded simply to
reduce noise. The contribution of those variables to the structured noise may also
be used to distinguish experimental conditions or to understand what experimen-
tal parameters are most important to control.
. Discussion
In this chapter, we have examined the nature of cytokine interactions between
spleen and serum using a powerful statistical technique, o-pls. We have estab-
lished that this is a biologically relevant question that can now be addressed much
more thoroughly with new xMap techniques. We have explained the features of
o-pls that make it an ideal choice for analyzing such data. And, using data from
recent experiments on L. monocytogenes infection of mice, we have demonstrated
the power of o-pls to extract essential information from an overwhelming wealth
of cytokine levels. Our o-pls models are robust. We used them to identify the
most relevant cytokines, show how cytokine levels in the serum related to those in
the spleen, cluster the observations into meaningful time-based groups, and learn
a common temporal and molecular signature of L. monocytogenes infection.
The most striking feature about the data and its analysis is the stark differences
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between serum and spleen cytokine levels that the model identified. These point
to a highly complex relationship between the two systems. To conclude, we sug-
gest some potential biological motivation for the most prevalent cytokines in our
model. These hypotheses represent a starting point for understanding the rela-
tionship between serum and spleen through experiment.
When combined with intuition and prior knowledge of the pathology of lis-
teriosis, the correlated groups of cytokines can be interpreted as hints about a
mechanistic understanding of L. monocytogenes infection, subject to the limits of
the data. Since the data were only collected at h. and h. timepoints, it seems
likely that the cytokine levels represent mostly inflammation and other innate im-
mune responses, rather than a strong adaptive response, as L. monocytogenes has
barely begun to enter the T cell zones by h. [, ]. Many of the cytokines
highlighted by the model as being in the core of infection are often associated with
innate responses to L. monocytogenes []. Based on previous research, we can
hypothesize a likely underlying mechanistic cause for each core cytokine. While
the hypotheses do not lead to a direct mechanistic picture themselves, they are a
wellspring of motivation for further experimental study.
One of the most highly expressed and widely-variable cytokines in the infec-
tious core was tnf-α. According to a widespread body of literature, this cytokine
is essential for a successful L. monocytogenes response [, ]. It is strongly
associated with macrophage expression and has recently been shown to associate
with dendritic cells as well []. Given its prominence in the acute inflammation
response, it is no surprise to see tnf-α throughout the models, likely indicating
macrophage and dendritic cell activity in the serum at h., and in the spleen at
h. This activation seems to be tempered somewhat by the presence of tgf-β.
tgf-β is known to suppress many of the effects of macrophage activation [].
It is reasonable to expect its more pronounced prevalence in the L. m.-L.p.FlaA

infection, which tends to be weaker. Finally, mip-1α, another key component of
the infectious core, is produced by macrophages, as its name implies, and clearly
indicates their presence in the spleen at h..
A second set of cytokines, consistently identified by the model in the serum
at h. is il-12p7 and, in the case of L. m.-L.p.FlaA, ifn-γ. These cytokines are
strongly associated with NK cells. ifn-γ is an inflammatory cytokine that is pro-
duced by activated T and NK cells and activates macrophages (among its many
functions). It is frequently cited as an essential cytokine for a successful host
defense [, ], and becomes even more important later on during T cell re-
sponses. Its presence in the serum at h. is likely due to its innate immune ef-
fects, while its presence in the spleen at h. may already be due to T cell activ-
ity [,].
Both tnf-α and il-12p7, which are expressed at h., are involved in lympho-
cyte proliferation and differentiation. The later is a chemokine that specifically
attracts monocytes, memory T-helper cells and eosinophils. Therefore, a combi-
nation of control of migration and differentiation is revealed in the spleen at h..
At h., based on the expression of ifn-γ and mip-1α, the spleen is a site of ac-
tive inflammatory responses, driven by macrophage-related cytokines. This is in
agreement with the role of macrophages and dendritic cells as the host cell for L.
monocytogenes.
Another uniquely strong signal in the model was il-5. Its main associations
include Th cd+ T cells, but it is also associated with mast cells [], which have
been shown to play an important role in early L. monocytogenes infection [].
il-6, known to be associated with tnf-α in triggering the acute stage of the
response [], is often seen as a key marker of L. monocytogenes infection. In
our observation, it was weakly, but consistently observed in the serum at h. of
infection. However, since liver samples were not measured in this dataset, and

thus Kupffer cells, a major source of il-6 [], were not incorporated, high levels
of il-6 were not observed, and it was not among the strongest signals.
The association of il-1β, a proxy for inflammasome activation [] in the
model was surprising. Despite Sauer et al.’s observation that wild-type L. mono-
cytogenes released low il-1β levels [], the cytokine was still identified as a
relatively reliable indicator of wild-type infection in the spleen at h. In the
L. m.-L.p.FlaA infection, designed and observed to elicit strong inflammasome ac-
tivation [], il-1β levels varied highly from mouse to mouse and were thus as-
sociated strongly with the orthogonal component, rather than with the predictive
model. The models’ classifications are not inconsistent with experiments, as they
address different properties: il-1β’s grouping depends less on its overall level than
it does on its variability across time and across mouse. In this context it is also im-
portant to note that il-1β is very hard to measure in sera and spleen (due to poor
reagents) and that the aim inflammasome can be activated by dna from dead L.
monocytogenes and confound the observation []. Since our experiments did not
include a test for il-18, another cytokine that is secreted as a result of inflamma-
some activation, we cannot specifically address the magnitude of inflammasome
activation in this experiment.
The biological associations implied by the detection of a variety of cytokines
are useful indicators of future experimental hypotheses. There are also other di-
rections for extending this work. Most prominent among these is extension along
the time axis. Since adaptive immune responses are much stronger at h. and be-
yond, but L. m.-L.p.FlaA is cleared by h., an o-pls model of data at such time-
points up to h. would be an even richer, more valuable compass in the forest
of analysis. Furthermore, there are other biomarkers which would be fascinating
to include in the model—from intercellular proteins such as MyD, known to
be essential in macrophage regulation [], to Toll-like surface receptors. Gene

expression data for key proteins could also be a useful tool. The ability of o-pls
to successfully juxtapose and combine multiple kinds of data into a single, all-
encompassing model would make it an essential tool in these analyses.
Thus, o-pls is a powerful latent variable regression technique that can take
large, systematic datasets and extract meaningful information from them, suggest
associations, cluster data, motivate mechanistic understanding, and suggest future
experiments. Despite its lack of intense computation and its underlying simplicity,
the technique holds tremendous promise in biology, and we hope future immunol-
ogists will consider its use to bring clarity and order to complex, multidimensional
datasets.
. Methods
.. Data collection
The data used in our analyses [] was collected by the Stanford Human Im-
mune Monitory Center using Panomics beads and Luminex  is or Luminex 
machines. Cytokine levels in the spleen and serum were collected using antibody-
coated, fluorescent (xMap) beads []. Spleen and serum data were collected on
separate plates.
.. Data normalization
Because of differences in background fluorescence levels between the two plates
and among the  different cytokines, the data were normalized as follows:
. Levels of each cytokine were rescaled relative to the mfi at the center of the
concentration curve
. A center value was calculated for each cytokine using the rescaled mfi values

. A background cutoff value was calculated as 130% of the current background
levels. The 130% scale factor was determined visually as the most conserva-
tive estimate of mfi levels at which spurious background signal would not be
accidentally detected
. The mfi values from each plate were shifted symmetrically so that the center
values for each cytokine were equal between the two plates
. Any mfi values below the background cutoff were set to zero
. An outlier-less th percentile was calculated for each cytokine, with out-
liers defined as any mfis greater than 32 the interquartile range
. Every cytokine’s mfis were rescaled by the 100th percentile
The normalization ensured that mfis obtained on one plate could be compared to
those from another plate, that the data was not biased toward cytokines with better
antibodies, and that spurious mfi signals were not treated as data.
In every model, samples with known extenuating experimental issues were re-
moved (both samples per mouse). Finally, for all three models, any variable which
fewer than two nonzero data points for the samples in the model was excluded
from the model. This simple preprocessing is a sanity check, as compared to
the much more complex variable selection preprocessing procedures required for
other kinds of regression models [,–].
.. Statistical modeling
The normalized and filtered data was sample-replicated. Since each mouse con-
tained two independent samples, both for the serum and the spleen, the data was
replicated so that each serum sample was paired with both spleen samples, and
vice versa. o-pls models of the replicated data were constructed using software

written from scratch in Matlab [], based on algorithms outlined in the pa-
pers that defined the method and its extensions [, , , ]. Based on pre-
vious approaches to choosing the optimal number of components [, ], the
optimal number of components was chosen for each model using leave-one-out
(loo) cross-validation and a steepest-descent minimization scheme. First, the loo
mean-squared error (mse) of cross-validation was calculated for models with all
valid combinations of predictive, X-orthogonal and Y -orthogonal dimensions a,
aYo ≤ a, and aXo ≤ a, producing a three-dimensional grid. The error minimization
was then performed in two stages. In the first stage, the optimal a was chosen by
calculating the median mse for each a across all valid combinations of aYo and aXo ,
and applying a steepest-descent search, starting at a = 1. Once the optimal a was
fixed, the optimal aYo and aXo were chosen by steepest descent minimization of
the mse starting at aYo = 0, aXo = 0. The minimizations converged rapidly to local
minima. The optimal a, aYo , and aXo found by the minimization scheme agreed
with the values chosen by the scree plot method [,].

(a) No Infection
Figure -: Plotting the serum cytokine levels against the spleen cytokine levels
demonstrates the complexity of the correlations between the two. Each plot repre-
sents the levels of one cytokine in the serum plotted against the corresponding
cytokine in the spleen, as a function of time. Its background color represents
the value of r, the Pearson correlation coefficient for the data. Rarely is a cy-
tokine in the serum strongly correlated to itself in the spleen; sometimes, it is
anti-correlated. Furthermore, there are substantial off-diagonal correlations be-
tween groups of cytokines. A latent variable regression model, such as o-pls,
tames this complexity.

(b) L. monocytogenes Infection
Figure -

(c) L. m.-L.p.FlaA Infection
Figure -

(a) The dataset (b) Planes defined by o-pls
(c) The predictive biplot (d) The orthogonal biplot
Figure -: An example dataset explains the power of o-pls for modeling high-
dimensional data and describes biplots. (a) The original dataset is difficult to visu-
alize. The threeX-dimensions il-1, il-2, and il-3, are represented spatially, and the
two Y -dimensions tnf-α andmip-1α represented with color. The Y data are plotted
as a color mixture, with blue representing tnf-α and pink representing mip-1α. (b)
o-pls finds reduced-dimensional subspaces onto which the data can be projected,
using both predictive and orthogonal data. The predictive subspace is green, while
the orthogonal subspace is yellow. (c) A biplot in the space of the first two predic-
tive components identifies clear trends in the data and explains those trends in
terms of the X-variables. Both dimensions of Y are projected cleanly. (d) A biplot
in the space of the first predictive and first orthogonal component. The vertical
dimension of the pattern in the Y data is no longer visible.
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(b) L. monocytogenes Infection
Figure -: Biplots of the o-pls models highlight the separation of the data into
h. and h. groups that differ between serum and spleen, identify the cytokines
most relevant to the spleen-serum relation, highlight a common cytokine signa-
ture for L. monocytogenes infection, and identify the cytokines responsible for dif-
ferences between infection variants. They simultaneously show the impact of each
cytokine on separating the data into time clusters (abscissa), and the impact of
each cytokine on the correlated noise (ordinate). The rotation of the triangles rep-
resents the mouse id of a sample: Mouse  = 4, Mouse  = 5, Mouse  = C, Mouse
 = B.
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Figure -: Grouping the mfi data by time-point shows the differences in cytokine
level that define the time separation. The plots showmfi level as a function of time.
Cytokines associated in the biplot with h. time points (yellow) tend to either
have higher levels at h. than at h. or not grow as rapidly by h. as cytokines
associated with the h. time points in the biplot. The plots also explain why
no time separation was found for the uninfected spleen: its cytokine levels remain
virtually unchanged across time. Only cytokines with a loading magnitude greater
than the th percentile are highlighted, while the rest are gray. The thickness
of a line denotes the relative magnitude of that cytokine’s loading in predictive
component .
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Figure A-: Backbone rmsd calculations show that the molecular dynamics sim-
ulations are stable. The plots show the rmsd of backbone Cα, C, N, and O atoms
from the original crystal structure coordinates, aligned to compensate for rotation
and translation. In addition to the total rmsd, the rmsd of each constituent pro-
tein segment is also shown. The region of trajectories used in the contact footprint
analysis (between 10 ns and 15 ns) is highlighted in gray. In this region, the total
rmsd values are relatively plateaued. rmsd values after equilibration are generally
high, especially for the mutant peptides, but this mostly reflects the fact that the
original crystal structure is a poor reference for the equilibrated mutant peptide
structures, as it does not take into account any conformational changes necessary
to accommodate the new peptides. Furthermore, most of the large rmsd deviations
are due to the mhc, particularly the α1 and α2 helices (data not shown), which are
responsible for maintaining the peptide groove.

Table A.: Calculated binding free energies are consistent with experiments
tcr pmhc Simulation ∆G (kcal/mol) Experimental ∆G (kcal/mol)
c ql-ld −3.2± 11 −7.6± 0.07
m ql-ld −24.7± 14 −9.0± 0.2
Binding free energies (∆G) calculated from the molecular dynamics trajectory
are qualitatively consistent with experimentally measured binding free energies.
Simulation binding free energies were calculated using the mm-gbsa method,
[,], averaged over the last 5ns of the trajectory. The mm-gbsa protocol was
adapted from the tcr/pmhc mm-gbsa simulations of Zoete et al. [], with the
exception of the entropy term. This term is likely to affect the actual values of
∆G obtained but is not expected to qualitatively change the order of the binding
affinities. The comparison shows that our simulations reproduce the experimental
finding that m binds more strongly to ql-ld than c. Errors are s.d.
 Experimental free energies were obtained by Jones et al. [] Errors are s.d.

Table A.: The changes in tcr/mhc contacts upon peptide mutation from cp to
ca are numerically significant
System A r¯c(A;α1) r¯c(A;α2)
cp 71.4± 0.8 156.1± 0.9
ca 72.4± 0.8 156.0± 1.0
cp 69.5± 0.8 156.7± 0.7
ca 73.5± 1.0 153.5± 0.8
mp 71.1± 0.8 156.7± 0.6
cx 73.3 156.3
mx 74.0 156.3
bm./pbm-kb 71.9 154.0
bm./vsv-kb 69.7 154.5
Mean positions, r¯c, of the contact distributions shown in Figure - and Figure -
 show a noticeably larger change in r¯c upon mutation from pca to pca-a (ca
vs. cp). These data are displayed visually in Figure -. The bottom two rows are
calculated from crystal structures obtained by Reiser, et al. [,] and compare
the r¯c values of two tcr/allo-pmhc complexes with the same tcr (bm.) and mhc
(kb), but different peptides (pbm and vsv). Comparing these crystal structures
to cx and mx, peptide mutation is shown to impact r¯c more than cdrα muta-
tion, in qualitative agreement with our simulation results. Errors reported for the
simulations are s.e.m.

Bibliography
[] Kranz, D. M.; Sherman, D. H.; Sitkovsky, M. V.; Pasternack, M. S.; Eisen,
H. N. Proceedings of the National Academy of Sciences of the USA , ,
.
[] Unanue, E. R. Annual Review of Immunology , , –.
[] McConnell, H. M.; Wada, H. G.; Arimilli, S.; Fok, K. S.; Nag, B. Proceedings
of the National Academy of Sciences of the USA , , .
[] Fowler, K. D.; Kuchroo, V. K.; Chakraborty, A. K. PloS One , , e.
[] Abel, S. M.; Roose, J. P.; Groves, J. T.; Weiss, A.; Chakraborty, A. K. Journal of
Physical Chemistry B , , –.
[] Govern, C. C.; Yang, M.; Chakraborty, A. K. Physical Review Letters ,
, .
[] Won, J.-H.; Goldberger, O.; Shen-Orr, S. S.; Davis, M. M.; Olshen, R. A. Pro-
ceedings of the National Academy of Sciences of the USA , , –.
[] Dahirel, V.; Shekhar, K.; Pereyra, F.; Miura, T.; Artyomov, M.; Talsania,
S.; Allen, T. M.; Altfeld, M.; Carrington, M.; Irvine, D. J.; Walker, B. D.;
Chakraborty, A. K. Proceedings of the National Academy of Sciences of the USA
, , –.
[] Wolfson, M. Y.; Nam, K.; Chakraborty, A. K. Journal of Physical Chemistry B
, , –.
[] Rivet, C. A.; Hill, A. S.; Lu, H.; Kemp, M. L. Molecular and Cellular Proteomics
, .
[] Ferguson, A. L.; Panagiotopoulos, A. Z.; Debenedetti, P. G.; Kevrekidis, I. G.
Proceedings of the National Academy of Sciences of the USA , , .
[] Kosˇmrlj, A.; Chakraborty, A. K.; Kardar, M.; Shakhnovich, E. I. Physical Re-
view Letters , , .

[] Alder, B. J.; Wainwright, T. E. Journal of Chemical Physics , , .
[] Frenkel, D.; Smit, B. Understanding Molecular Simulation: from Algorithms to
Applications, nd ed.; Academic: San Diego, Calif. ; London, .
[] Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.;
Karplus, M. Journal of Computational Chemistry , , –.
[] Brooks, C. L.; Karplus, M.; Pettitt, B. M. Proteins: a theoretical perspective of
dynamics, structure, and thermodynamics; Advances in chemical physics ; v.
; J. Wiley: New York, .
[] Karplus, M.; McCammon, J. A. Nature Structural Biology , , –.
[] Garboczi, D. N.; Ghosh, P.; Utz, U.; Fan, Q. R.; Biddison, W. E.; Wiley, D. C.
Nature , , –.
[] Reiser, J. B.; Darnault, C.; Gre´goire, C.; Mosser, T.; Mazza, G.; Kearney, A.;
van der Merwe, P. A.; Fontecilla-Camps, J. C.; Housset, D.; Malissen, B. Na-
ture Immunology , , –.
[] Pai, E. F.; Krengel, U.; Petsko, G. A.; Goody, R. S.; Kabsch, W.; Wittinghofer,
A. EMBO Journal , , –.
[] Arkin, M. R.; Randal, M.; DeLano, W. L.; Hyde, J.; Luong, T. N.; Oslob, J. D.;
Raphael, D. R.; Taylor, L.; Wang, J.; McDowell, R. S.; Wells, J. A.; Braisted,
A. C. Proceedings of the National Academy of Sciences of the USA , ,
–.
[] Freddolino, P. L.; Arkhipov, A. S.; Larson, S. B.; McPherson, A.; Schulten, K.
Structure (London, England : ) , , –.
[] MacKerell Jr, A. D.; et al. Journal of Physical Chemistry B , , –
.
[] Jones, J. E. Proceedings of the Royal Society A , , –.
[] Sethi, A.; Goldstein, B.; Gnanakaran, S. PLoS Computational Biology , ,
e.
[] Louet, M.; Perahia, D.; Martinez, J.; Floquet, N. Journal of Molecular Biology
, , –.
[] Levin, A. M.; Bates, D. L.; Ring, A. M.; Krieg, C.; Lin, J. T.; Su, L.; Moraga,
I.; Raeber, M. E.; Bowman, G. R.; Novick, P.; Pande, V. S.; Fathman, C. G.;
Boyman, O.; Garcia, K. C. Nature , , .
[] Wan, S. Z.; Coveney, P. V.; Flower, D. R. Journal of Immunology , ,
–.

[] Zoete, V.; Michielin, O. Proteins: Structure, Function, and Bioinformatics ,
, –.
[] Michielin, O.; Karplus, M. Journal of Molecular Biology , , –.
[] Andrienko, N.; Andrienko, G. Exploratory Analysis of Spatial And Temporal
Data: A Systematic Approach, xvi ed.; Springer: Berlin, .
[] Kellar, K. L.; Kalwar, R. R.; Dubois, K. A.; Crouse, D.; Chafin, W. D.; Kane,
B. E. Cytometry , , –.
[] Perfetto, S. P.; Chattopadhyay, P. K.; Roederer, M. Nature Reviews Immunology
, , –.
[] Janes, K. A.; Kelly, J. R.; Gaudet, S.; Albeck, J. G.; Sorger, P. K.; Lauffenburger,
D. A. Journal of Computational Biology , , –.
[] Janes, K. A.; Albeck, J. G.; Gaudet, S.; Sorger, P. K.; Lauffenburger, D. A.;
Yaffe, M. B. Science , , –.
[] Carrari, F.; Baxter, C.; Usadel, B.; Urbanczyk-Wochniak, E.; Zanor, M.-I.;
Nunes-Nesi, A.; Nikiforova, V.; Centero, D.; Ratzka, A.; Pauly, M.; Sweet-
love, L. J.; Fernie, A. R. Plant Physiology , , –.
[] Kemp, M. L.; Wille, L.; Lewis, C. L.; Nicholson, L. B.; Lauffenburger, D. A.
Journal of Immunology , , .
[] Jolliffe, I. T. Principal Component Analysis, nd ed.; Springer Series in Statis-
tics; Springer-Verlag: New York, .
[] Gabriel, K. R. Biometrika , , –.
[] Draper, N. R.; Smith, H. Applied Regression Analysis; Wiley Series in Proba-
bility and Statistics, Vol. ; Wiley, .
[] Kendall, M. G. A Course in Multivariate Analysis, nd ed.; Hafner Pub. Co.:
New York, .
[] de Jong, S. Chemometrics and Intelligent Laboratory Systems , , –
.
[] Wold, S.; Sjo¨stro¨m, M.; Eriksson, L. Chemometrics and Intelligent Laboratory
Systems , , –.
[] Martens, H.; Martens, M. Multivariate analysis of quality: an introduction;
John Wiley & Sons Inc., .
[] Trygg, J.; Wold, S. Journal of Chemometrics , , –.
[] Wold, H. Research Papers in Statistics , , –.

[] Zou, X.; Zhao, J.; Mao, H.; Shi, J.; Yin, X.; Li, Y. Applied Spectroscopy ,
, –.
[] Hasegawa, K.; Funatsu, K. SAR and QSAR in Environmental Research ,
, –.
[] Xiaobo, Z.; Jiewen, Z.; Povey, M. J. W.; Holmes, M.; Hanpin, M. Analytica
Chimica Acta , , –.
[] Boulesteix, A.-L.; Strimmer, K. Briefings in Bioinformatics , , –.
[] Hasegawa, K.; Miyashita, Y.; Funatsu, K. Journal of Chemical Information and
Computer Sciences , , –.
[] Kimura, T.; Hasegawa, K.; Funatsu, K. Journal of Chemical Information and
Computer Sciences , , –.
[] Hasegawa, K.; Kimura, T.; Funatsu, K. Journal of Chemical Information and
Computer Sciences , , –.
[] Gao, H.; Lajiness, M. S.; Drie, J. V. Journal of Molecular Graphics and Modeling
, , –.
[] Hasegawa, K.; Kimura, T.; Funatsu, K. Quantitative Structure-Activity Rela-
tionships , , –.
[] Wold, S. Chemometrics and Intelligent Laboratory Systems , , –.
[] Trygg, J.; Wold, S. Journal of Chemometrics , , –.
[] Malinowski, E. R. Factor analysis in chemistry, nd ed.; Wiley, .
[] Lo¨fstedt, T.; Trygg, J. Journal of Chemometrics , –.
[] Yu, H.; MacGregor, J. F. Chemometrics and Intelligent Laboratory Systems ,
, –.
[] Ergon, R. Journal of Chemometrics , , –.
[] Kemsley, E. K.; Tapp, H. S. Journal of Chemometrics , , –.
[] Hogquist, K. A.; Jameson, S. C.; Bevan, M. J. Current Opinions in Immunology
, , –.
[] Jameson, S. C.; Hogquist, K. A.; Bevan, M. J. Annual Review of Immunology
, , –.
[] Werlen, G.; Hausmann, B.; Naeher, D.; Palmer, E. Science , , .
[] Starr, T. K.; Jameson, S. C.; Hogquist, K. A. Annual Review of Immunology
, , –.

[] von Boehmer, H.; Aifantis, I.; Gounari, F.; Azogui, O.; Haughn, L.; Apos-
tolou, I.; Jaeckel, E.; Grassi, F.; Klein, L. Immunological Reviews , ,
–.
[] Hogquist, K. A.; Baldwin, T. A.; Jameson, S. C. Nature Reviews Immunology
, , –.
[] Siggs, O. M.; Makaroff, L. E.; Liston, A. Current Opinions in Immunology
, , –.
[] Kosˇmrlj, A.; Jha, A. K.; Huseby, E. S.; Kardar, M.; Chakraborty, A. K. Proceed-
ings of the National Academy of Sciences of the USA , , –.
[] Huseby, E. S.; White, J.; Crawford, F.; Vass, T.; Becker, D.; Pinilla, C.; Mar-
rack, P.; Kappler, J. W. Cell , , –.
[] Huseby, E. S.; Crawford, F.; White, J.; Marrack, P.; Kappler, J. W. Nature Im-
munology , , –.
[] Lindahl, K. F.; Wilson, D. B. Journal of Experimental Medicine , , –
.
[] Lynes, M. A.; Flaherty, L.; Michaelson, J.; Collins, J. J.; Rinchik, E. M. Journal
of Immunogenetics , , –.
[] Lechler, R. I.; Lombardi, G.; Batchelor, J. R.; Reinsmoen, N.; Bach, F. H. Im-
munology Today , , –.
[] Kaufman, C. L.; Gaines, B. A.; Ildstad, S. T. Annual Review of Immunology
, , –.
[] Joyce, S.; Nathenson, S. G. Immunological Reviews , , –.
[] Le, N. T.; Chen, B. J.; Chao, N. J. Cytotherapy , , –.
[] Hauben, E.; Bacchetta, R.; Roncarolo, M. G. Cytotherapy , , –.
[] Felix, N. J.; Allen, P. M. Nature Reviews Immunology , , –.
[] Nikolich-Zugich, J. Nature Immunology , , –.
[] Colf, L. A.; Bankovich, A. J.; Hanick, N. A.; Bowerman, N. A.; Jones, L. L.;
Kranz, D. M.; Garcia, K. C. Cell , , –.
[] DeLano, W. L.; The PyMOL User’s Manual; Palo Alto, CA, USA; .
[] Alexander-Miller, M. A.; Burke, K.; Koszinowski, U. H.; Hansen, T. H.; Con-
nolly, J. M. Journal of Immunology , , –.
[] Basu, D.; Horvath, S.; Matsumoto, I.; Fremont, D. H.; Allen, P. M. Journal of
Immunology , , –.

[] Eisen, H. N. Annual Review of Immunology , , –.
[] Huseby, E. S.; Crawford, F.; White, J.; Kappler, J.; Marrack, P. Proceedings of
the National Academy of Sciences of the USA , , –.
[] Panina-Bordignon, P.; Corradin, G.; Roosnek, E.; Sette, A.; Lanzavecchia, A.
Science , , –.
[] Udaka, K.; Tsomides, T. J.; Eisen, H. N. Cell , , –.
[] Garcia, K. C.; Adams, E. J. Cell , , –.
[] Armstrong, K. M.; Piepenbrink, K. H.; Baker, B. M. Biochemical Journal ,
, –.
[] Felix, N. J.; Donermeyer, D. L.; Horvath, S.; Walters, J. J.; Gross, M. L.; Suri,
A.; Allen, P. M. Nature Immunology , , –.
[] Hornell, T. M.; Martin, S. M.; Myers, N. B.; Connolly, J. M. Journal of Im-
munology , , –.
[] Garcia, K. C.; Degano, M.; Pease, L. R.; Huang, M.; Peterson, P. A.; Teyton,
L.; Wilson, I. A. Science , , –.
[] Ding, Y. H.; Baker, B. M.; Garboczi, D. N.; Biddison, W. E.; Wiley, D. C.
Immunity , , –.
[] Degano, M.; Garcia, K. C.; Apostolopoulos, V.; Rudolph, M. G.; Teyton, L.;
Wilson, I. A. Immunity , , –.
[] Hahn, M.; Nicholson, M. J.; Pyrdol, J.; Wucherpfennig, K. W. Nature Im-
munology , , –.
[] Borbulevych, O. Y.; Piepenbrink, K. H.; Gloor, B. E.; Scott, D. R.; Sommese,
R. F.; Cole, D. K.; Sewell, A. K.; Baker, B. M. Immunity , , –.
[] Burrows, S. R.; et al. Proceedings of the National Academy of Sciences of the
USA , , .
[] Reiser, J. B.; Darnault, C.; Guimezanes, A.; Gregoire, C.; Mosser, T.; Schmitt-
Verhulst, A. M.; Fontecilla-Camps, J. C.; Malissen, B.; Housset, D.; Mazza, G.
Nature Immunology , , –.
[] Luz, J. G.; Huang, M.; Garcia, K. C.; Rudolph, M. G.; Apostolopoulos, V.;
Teyton, L.; Wilson, I. A. Journal of Experimental Medicine , , .
[] Reiser, J. B.; Gre´goire, C.; Darnault, C.; Mosser, T.; Guimezanes, A.; Schmitt-
Verhulst, A. M.; Fontecilla-Camps, J. C.; Mazza, G.; Malissen, B.; Housset, D.
Immunity , , –.

[] Archbold, J. K.; Macdonald, W. A.; Miles, J. J.; Brennan, R. M.; Kjer-Nielsen,
L.; McCluskey, J.; Burrows, S. R.; Rossjohn, J. Journal of Biological Chemistry
, , .
[] Jones, L. L.; Colf, L. A.; Bankovich, A. J.; Stone, J. D.; Gao, Y. G.; Chan, C. M.;
Huang, R. H.; Garcia, K. C.; Kranz, D. M. Biochemistry , , .
[] Jones, L. L.; Colf, L. A.; Stone, J. D.; Garcia, K. C.; Kranz, D. M. Journal of
Immunology , , .
[] Gras, S.; Burrows, S. R.; Kjer-Nielsen, L.; Clements, C. S.; Liu, Y. C.; Sullivan,
L. C.; Bell, M. J.; Brooks, A. G.; Purcell, A. W.; McCluskey, J.; Rossjohn, J.
Immunity , , –.
[] MacDonald, W. A.; et al. Immunity , , –.
[] Wu, L. C.; Tuot, D. S.; Lyons, D. S.; Garcia, K. C.; Davis, M. M. Nature ,
, –.
[] Eisen, H. N.; Chakraborty, A. K. Proceedings of the National Academy of Sci-
ences of the USA , , .
[] Bru¨nger, A. T. Proteins: Structure, Function, and Genetics , , –.
[] Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L.
Journal of Chemical Physics , , –.
[] Brooks, B. R.; et al. Journal of Computational Chemistry , , –.
[] Mackerell Jr, A. D.; Feig, M.; Brooks III, C. L. Journal of Computational Chem-
istry , , –.
[] van Gunsteren, W. F.; Berendsen, H. J. C. Molecular Physics , , –
.
[] Steinbach, P. J.; Brooks, B. R. Journal of Computational Chemistry , ,
–.
[] Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G.
Journal of Chemical Physics , , –.
[] Nose´, S. Journal of Chemical Physics , , –.
[] Hoover, W. G. Physical Review A , , –.
[] Feller, S. E.; Zhang, Y.; Pastor, R. W.; Brooks, B. R. Journal of Chemical Physics
, , .
[] Eisen, H. N.; Sykulev, Y.; Tsomides, T. J. Advances in Protein Chemistry ,
, –.

[] Kageyama, S.; Tsomides, T. J.; Fukusen, N.; Papayannopoulos, I. A.; Eisen,
H. N.; Sykulev, Y. Journal of Immunology , , .
[] Sha, W. C.; Nelson, C. A.; Newberry, R. D.; Kranz, D. M.; Russell, J. H.; Loh,
D. Y. Nature , , –.
[] Humphrey, W.; Dalke, A.; Schulten, K. Journal of Molecular Graphics ,
, –.
[] Gattinoni, L.; Powell, D. J.; Rosenberg, S. A.; Restifo, N. P. Nature Reviews
Immunology , , –.
[] TreeStar Software; FlowJo; . http://www.flowjo.com/.
[] Naumann, T.; Schiller, H. Formulae and Methods in Experimental Data Evalu-
ation .
[] Knijnenburg, T. A.; Roda, O.; Wan, Y.; Nolan, G. P.; Aitchison, J. D.; Shmule-
vich, I. Molecular Systems Biology , , .
[] Tumeh, P. C.; Koya, R. C.; Chodon, T.; Graham, N. A.; Graeber, T. G.; Comin-
Anduix, B. n.; Ribas, A. Journal of Immunotherapy , , –.
[] Comin-Anduix, B. n.; Ribas, A. Unpublished .
[] Trygg, J. Journal of Chemometrics , , –.
[] Athanassakis, I.; Iconomidou, B. Developmental Immunology , , –
.
[] Nakane, A.; Numata, A.; Minagawa, T. Infection and Immunity , , –
.
[] Goldberger, O.; Sauer, J.-D.; Davis, M. M. Unpublished .
[] Jeffers, J. N. R. Journal of the Royal Statistical Society C , ,  – .
[] Bylesjo¨, M.; Eriksson, D.; Kusano, M.; Moritz, T.; Trygg, J. Plant Journal ,
, –.
[] Abdi, H. In Encyclopedia of Social Sciences Research Methods; Lewis-Beck, M.;
Bryman, A.; Futing Liao, T., Eds.; Sage: Thousand Oaks, CA, ; Vol. ,
pp –.
[] Zhang, K.; Kim, S.; Cremasco, V.; Hirbe, A. C.; Collins, L.; Piwnica-Worms,
D.; Novack, D. V.; Weilbaecher, K.; Faccio, R. Cancer Research , , –
.
[] Yang, Z.-Z.; Grote, D. M.; Ziesmer, S. C.; Manske, M. K.; Witzig, T. E.; Novak,
A. J.; Ansell, S. M. Blood , , –.

[] Neurath, M. F.; Hildner, K.; Becker, C.; Schlaak, J. F.; Barbulescu, K.; Ger-
mann, T.; Schmitt, E.; Schirmacher, P.; Haralambous, S.; Pasparakis, M.;
Meyer Zum Bu¨schenfelde, K. H.; Kollias, G.; Ma¨rker-Hermann, E. Clinical
and Experimental Immunology , , –.
[] Sauer, J.-D.; Pereyre, S.; Archer, K. A.; Burke, T. P.; Hanson, B.; Lauer, P.;
Portnoy, D. A. Proceedings of the National Academy of Sciences of the USA ,
, –.
[] Kirkland, K. L.; Sillito, A. M.; Jones, H. E.; West, D. C.; Gerstein, G. L. Journal
of Neurophysiology , , –.
[] Langermans, I. A.; van Furth, R. Biotherapy , , –.
[] Pamer, E. G. Nature Reviews Immunology , , –.
[] Conlan, J. W. Journal of Medical Microbiology , , .
[] Geginat, G.; Grauling-Halama, S. In Handbook of Listeria Monocytogenes;
CRC Press, ; Chapter , pp –.
[] Deluca, L. S.; Gommerman, J. L. Nature Reviews Immunology , , –
.
[] Kitamura, M. Journal of Immunology , , –.
[] Shakoory, B.; Fitzgerald, S. M.; Lee, S. A.; Chi, D. S.; Krishnaswamy, G. Jour-
nal of Interferon and Cytokine Research , , –.
[] Gekara, N. O.; Weiss, S. Cellular Microbiology , , –.
[] Witte, C. E.; Archer, K. A.; Rae, C. S.; Sauer, J.-D.; Woodward, J. J.; Portnoy,
D. A. Advances in Immunology , , –.
[] The Mathworks; Matlab; . http://mathworks.com/.
[] Wold, S. Technometrics , ,  – .
[] Srinivasan, J.; Cheatham III, T. E.; Cieplak, P.; Kollman, P. A.; Case, D. A.
Journal of the American Chemical Society , , –.
[] Kollman, P. A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee,
M.; Lee, T.; Duan, Y.; Wang, W.; Donini, O.; Cieplak, P.; Srinivasan, J.; Case,
D. A.; Cheatham III, T. E. Accounts of Chemical Research , , –.

